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Abstract 
Hepatitis C virus (HCV) is a small RNA encoded virus that causes acute and chronic 
infections of the liver and is associated with fibrosis, cirrhosis, hepatocellular carcinoma 
and end-stage liver disease. The infection is linked with elevated serum ferritin levels and 
iron deposits within the liver which are associated with an increased risk of progression of 
HCV  disease.  It  is  hypothesised  firstly  that the  presence  of  excess  iron  affects  HCV 
replication and secondly that iron homeostasis is altered by HCV replication. The main 
aim of this study was to investigate the influence of iron on HCV replication by analysing 
the spread of infection and the titre of infectious HCV produced in the presence of excess 
iron. The second aim was to determine if HCV infection itself alters the level of iron 
stored as ferritin in liver cells. 
 
HCV Japanese fulminant hepatitis (JFH-1) infection of the human hepatoma cell line, 
(Huh7), was used as the model for this study. The culture conditions were first optimised 
to allow detection of  ferritin  by western  blot. Huh7 cells were then treated with  iron 
provided by 5, 10 or 20 μg/ml ferric ammonium citrate (FAC) prior to HCV infection 
(0.001 MOI). No evidence of inhibition of HCV replication was found on day 7 post 
infection  (PI)  by  analysis  of  the  level  of  viral  protein  detected  by  western  blot,  the 
proportion of infected cells determined by immunohistochemistry and flow cytometry or 
the titre of infectious HCV produced. A comparison of iron donors was then undertaken 
and conditions were changed to add iron donors 1 day after HCV. Viral RNA levels were 
not significantly reduced on treatment with 20 μg/ml FAC and 25 μM holo-transferrin 
and assays for viral protein and production of infectious virus again showed no evidence 
of inhibition. Fe-PIH, a lipophilic iron donor, had the greatest effect, reducing both the 
proportion of infected cells and the titre of infectious virus produced. When the reduction   iv 
in the number of cells present in cultures treated with Fe-PIH was taken into account, the 
decrease in virus titre was explained.  
   
HCV infection was found to alter iron storage in Huh7 cells. A significantly lower level 
of  ferritin  was  detected  (p  <  0.05)  by  western  blot  in  HCV  infected  compared  to 
uninfected Huh7 cells whereas in other situations highly infected cells were found to have 
increased  iron  storage.  While  it  had  been  intended  to  analyse  iron  metabolism  by 
examining gene expression during iron deficiency and iron storage, the conditions which 
give rise to these outcomes will need to be elucidated first. 
 
This study has shown that iron has the potential to inhibit HCV replication although in 
vitro it depends on the type and concentration of iron donor used and the time during 
infection  that  excess  iron  is  present  in  the  cell.  This  study  has  confirmed  that  HCV 
infection alters the iron status of the liver cell. The outcome of these interactions between 
iron and HCV is expected to influence the course of HCV infection and the development 
of liver disease.    v 
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Chapter 1:   Introduction 
1.1  Introduction to Hepatitis C Virus (HCV) 
1.1.1  Epidemiology of HCV 
Hepatitis C virus (HCV) is associated with fibrosis, cirrhosis, hepatocellular carcinoma 
and end-stage liver disease. It occurs worldwide, however the prevalence varies between 
countries (Castello et al., 2010; Gravitz, 2011; Yang and Roberts, 2010). The incidence 
rates are highest in South Asia and North Africa with more than 14% of the population 
infected in Egypt. By comparison, the prevalence of HCV is 1-1.9% in America and 2-
2.9% in Australia (Figure 1.1) (Gravitz, 2011). World Health Organisation estimates that 
3% of the world population is chronically infected with HCV (Castello et al., 2010).  
 
HCV is transmitted through direct exposure to infected blood. This may occur through 
intravenous  or  intranasal  drug  use,  high  risk  sexual  activity,  blood  transfusions, 
iatrogenic, needle-stick injury or vertical from mother to offspring (Gravitz, 2011; Yang 
and Roberts, 2010). The risk of contracting HCV via transfusions has dropped to less than 
0.03%  infection  per  unit  of  transferred  blood  in  developed  countries  since  the 
introduction of routine  HCV screening of donated blood  in 1992  (Yang and Roberts, 
2010). 
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Figure  1.1:  Global  prevalence  of  HCV  and  the  distribution  of  HCV  genotypes 
(Gravitz, 2011). 
 
There are at least six different HCV genotypes with up to 35% variation of viral genome 
with subtypes containing up to 25% variation. The genotypes are numbered (1, 2, 3, 4, 5, 
6) and subtypes are allocated a lowercase alphabetical letter (a, b, c) according to the 
order of discovery. Within a host, genetic variants of the genotypes (quasispecies) can 
occur due to the accumulation of mutations during replication. The open reading frame of 
each genotype varies in length; genotype 1 contains 9400 nucleotides while genotype 2 
contains  9099  nucleotides  (Zein,  2000).  The  genotype  affects  the  success  of  certain 
treatments; standard treatment is least effective against genotype 1 (Schlutter, 2011). The 
distribution of genotypes worldwide varies (Figure 1.1) (Gravitz, 2011); genotype 1 is 
widespread while others such as genotypes 10 and 11, which are only found in Indonesia, 
are localised to specific areas (Schlutter, 2011; Zein, 2000). Genotype 1 is predominant in Introduction  
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America, Europe, Asia and Australia while genotype 4 is the most common genotype in 
Africa (Gravitz, 2011).  
1.1.2  Acute and chronic HCV infection 
1.1.2.1 Acute HCV infection 
Acute HCV infection is often unrecognised due to absent or mild symptoms, with most 
(~75%) experiencing no symptoms at all (Bowen and Walker, 2005; Hoofnagle, 1997). 
The onset of symptoms occurs up to 7 weeks after initial infection however, HCV RNA is 
detectable by week 1 or 2 (Hoofnagle, 1997). The most common symptom is fatigue but 
malaise,  nausea,  loss  of  appetite,  anorexia,  dark  urine,  muscle  aches,  rash  and  rarely 
jaundice may occur depending on the severity of the infection (Bowen and Walker, 2005; 
Hoofnagle, 1997). About 15% of acute HCV infections resolve and HCV RNA levels 
become undetectable (Hoofnagle, 1997). However, this does not protect against future 
HCV  infections  (Bowen  and  Walker,  2005).  If  the  infection  is  not  cleared,  chronic 
infection occurs (Zein, 2000). The progression of HCV infection is shown in Figure 1.2. 
1.1.2.2 Chronic HCV infection 
Chronic HCV infection occurs when the host response is ineffective at viral clearance 
(Zein,  2000).  Fibrosis  of  the  liver  develops  as  a  result  of  injury  and  inflammation 
(Marcellin, Asselah, and Boyer, 2002). Tissue damage releases alanine aminotransferase 
(ALT),  found  mainly  in  the  liver,  into  the  bloodstream.  Elevated  serum  ALT  levels 
observed  in HCV  infection are  indicative of  liver status  (Isom, McDevitt, and Moon, 
2009).  Most  only  experience  mild  to  moderate  chronic  hepatitis  as  severe  chronic 
hepatitis is rare. Fibrosis in severe infections progresses to cirrhosis (Figure 1.2). The rate 
of  developing  cirrhosis  varies;  it  may  be  rapid,  occurring  in  2  to  3  years,  or  slow, Introduction  
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occurring 20 to 30 years after initial infection. Variceal haemorrhage, ascites and portal 
hypertension  are  associated  with  cirrhosis.  Cirrhosis  may  progress  to  hepatocellular 
carcinoma (HCC) or end-stage liver disease. Symptoms of end-stage liver disease include 
fluid  retention,  bruising,  upper  intestinal  haemorrhage,  jaundice,  fatigue,  muscle 
weakness, dark urine and itching. Advanced liver failure can result in confusion or coma 
due to the build-up of toxins. At this stage, liver transplantation is the only option to 
prevent death (Hoofnagle, 1997). 
 
 
 
Figure 1.2: Progression of HCV infection (Castello et al., 2010; Hoofnagle, 1997). 
 
There  are  a  number  of  factors  that  can  enhance  the  progression  of  HCV  infection. 
Duration of infection, co-infection, age, male gender, steatosis, obesity, diabetes/insulin 
resistance, and alcohol can all promote progression while genotype and viral load have 
little effect on the progression of HCV infection. Co-infection with other viruses, bacteria Introduction  
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or  fungi  can  enhance  the  progression  rate.  HIV  co-infection  suppresses  the  immune 
system decreasing clearance of HCV. Fibrosis is accelerated when infection occurs over 
the age of 50 and cirrhosis is more likely to develop when infected over the age of 40. 
Alcohol by itself is able to cause fibrosis and cirrhosis, thus worsening the effects of HCV 
(Marcellin, Asselah, and Boyer, 2002). 
 
HCV  does  not  only  affect  the  liver,  it  is  also  associated  with  non-hepatic 
diseases/conditions. HCV has been associated with arthritis, keratoconjunctivitis sicca, 
lichen  planus,  glomerulonephritis,  essential  mixed  cryoglobulinemia  and  porphyria 
cutanea tarda. Fatigue, muscle aches, arthritis, rash, neuropathy and glomerulonephritis 
are all symptoms of the systemic vasculitis. Porphyria cutanea tarda is associated with 
iron  overload  and  phlebotomy  has  been  used  as  a  treatment  to  remove  excess  iron 
(Hoofnagle, 1997). 
1.1.3  Diagnosis 
The standard diagnosis of HCV is through HCV antibody enzyme immunoassay. Blood is 
tested  for  HCV  antibodies.  If  antibodies  are  detected  a  confirmatory  recombinant 
immunoblot assay is preformed to detect viral RNA within the blood. If both tests are 
positive  for  HCV,  genotyping  and  quantitative  HCV  RNA  PCR  are  performed.  This 
process  can  take  up  to  a  month  to  complete  with  multiple  blood  tests  required  so 
alternative,  cheap  and  faster  tests  are  being  developed.  OraSure  Technologies  has 
developed a rapid 20 minutes antibody test that is similar to a pregnancy test. A finger 
prick or mouth swab is inserted into a vial, 2 red/purple lines represent presence of HCV 
antibodies (DeWeerdt, 2011). An alternative to PCR has been developed to detect HCV 
RNA  in  a  single  reaction  containing  serum,  gold  particles  and  oligotargets,  with  the 
solution appearing red in the absence of HCV RNA and blue in the presence of HCV Introduction  
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RNA. This test is cheaper, takes 30 minutes and could eliminate the need for antibody 
testing (Shawky, Bald, and Azzazy, 2010).   
1.1.4  Treatments 
1.1.4.1 Standard treatments 
The standard treatment for HCV is a combination  of antiviral ribavirin and pegylated 
interferon alpha (Yang and Roberts, 2010). Ribavirin is taken orally twice daily to inhibit 
viral replication with weekly injections of pegylated interferon alpha injections to boost 
the  immune  system  (Gravitz,  2011;  Schlutter,  2011).  Pegylation  of  interferon  alpha 
allows for a longer half-life, decreasing the frequency of doses from three times to once 
per week (Wang et al., 2002).  The effectiveness of the treatment depends upon the HCV 
genotype. This treatment is least effective against the predominant genotype 1 as only 
50%  of  patients  respond  to  treatment  (Pereira  and  Jacobson,  2009).  The  length  of 
treatment also varies depending on genotype; genotypes 1 and 4 require 48 weeks of 
treatment while genotypes 2 and 3 only require 24 weeks  (Wilkins et al., 2010). The 
treatment is not effective for everyone and a third of patients stop treatment due to the 
adverse side effects; including depression, fatigue, flu-like symptoms, anaemia, alopecia, 
and loss of appetite (Gravitz, 2011; Wilkins et al., 2010).  
1.1.4.2  Developing treatments 
As  the  current  standard  treatment  of  HCV  is  least  effective  with  the  predominant 
genotype 1, other drugs are being developed to target this problem; such as Boceprevir 
and  Telaprevir  (Gravitz,  2011).  Boceprevir  from  Merck  and  Telaprevir  from  Vertex 
Pharmaceuticals  are  currently  in  phase  III trials.  Both  are  direct-acting  antivirals  that 
target  HCV  directly.  The  drugs  are  protease  inhibitors  that  block  the  HCV  NS3/4A Introduction  
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protease  which  halts  replication  as  functional  and  structural  viral  proteins  are  not 
synthesised  (Schlutter,  2011).  These  treatments,  as  with  most  other  developing 
treatments,  are  used  in  combination  with  the  standard  pegylated  interferon  alpha 
treatment  (Asselah  and  Marcellin,  2011;  Schlutter,  2011).  Combination  therapies  are 
favoured as different viral factors can be targeted, limiting drug resistance (Pereira and 
Jacobson, 2009). The side effects of the original standard treatment still occur and there 
are the additional effects of these drugs. A small phase II trial is under way that aims to 
limit  the  side  effects  by  using  a  double  therapy  with  a  protease  inhibitor  and  NS5A 
inhibitor that does not contain interferon (Schlutter, 2011).  Boceprevir caused a metallic 
taste and anaemia but these affects were not severe enough to stop the trial (Asselah and 
Marcellin, 2011; Schlutter, 2011). Telaprevir caused gastrointestinal events, anaemia and 
a rash. The rash caused some subjects to discontinue the trial but it cleared upon stopping 
drug usage (Asselah and Marcellin, 2011). Trials have shown increased cure rates and 
better  viral  responses  to  genotype  1  with  Boceprevir  and  Telaprevir  (Asselah  and 
Marcellin, 2011).  
1.1.4.3 Alternative treatments  
Alternative  treatments  are  utilised  when  conventional  drug  therapies  fail  or  the  side 
effects cannot be tolerated. Studies have shown that decreasing iron levels through iron 
reduction therapy such as low-iron diet are beneficial for patients with HCV as it reduces 
inflammation, decreases oxidative damage, and could prevent the progression of fibrosis 
and emergence of hepatocellular carcinoma (Olynyk et al., 2007; Tanaka and Kiyosawa, 
2004). Silymarin, the active component of milk thistle, is one of the most common herbal 
supplements. Animal models have shown antioxidant, antifibrotic and anti-inflammatory 
properties (Verma and Thuluvath, 2007). Pilot studies suggest that ALT levels decrease 
but there is no change to HCV RNA levels (Seeff et al., 2001). Glycyrrhizin, a liquorice Introduction  
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root extract, has been used to treat a variety of liver diseases. In animal models of HCV 
infection it has antioxidant properties, prevented liver fibrosis and enhanced liver enzyme 
levels.  Clinical  trials  were  unsuccessful  in  producing  viral  clearance  and  side  effects 
included worse symptoms of cirrhosis (Seeff et al., 2001; Verma and Thuluvath, 2007). 
Acupuncture has been used to lessen postoperative pain but this therapy has an increased 
risk of HCV transmission (Verma and Thuluvath, 2007). There is not enough evidence to 
support the effectiveness of these alternative treatments. 
1.2  Virology of HCV 
1.2.1  HCV Genome structure and proteins 
The  HCV  genome  is  a  positive  RNA  strand  containing  a  single  open  reading  frame, 
encoding for around 3000 amino acid polyprotein. HCV is a small RNA virus and the 
genome encodes only around 10 products; the capsid protein, an ion channel essential for 
viral particle assembly (P7), envelope glycoproteins (E1 and E2) and enzymes including 
proteases, helicase and RNA dependent RNA polymerase essential for HCV replication 
(Figure 1.3). The functions of the HCV proteins are listed in table 1.1. Both the structural 
and non-structural components induce host responses (Smirnova et al., 2011). 
1.2.2  Viral life cycle 
The viral life cycle of HCV is depicted in Figure 1.4. HCV only causes infection within 
humans,  chimpanzees  and  Tupaia  belangeri,  targeting  hepatocytes  (Dolgin,  2011). 
Glycoproteins E1 and E2 of the HCV surface bind to cell receptors of the host to gain 
entry into the cell. Accepted target receptors include the tetraspanin protein CD81, low 
density lipoprotein receptor, scavenger receptor class B type I and claudin-1 (Asselah and 
Marcellin, 2011; Moradpour, Penin, and Rice, 2007).  Introduction  
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Figure  1.3:  HCV  Genome.  (a)  genome  structure  and  (b)  proteins  and  their  main 
functions (Smirnova et al., 2011). 
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Table 1.1: Functions of HCV proteins (Smirnova et al., 2011). 
Protein  Function 
Core  Forms viral capsid. Capable of regulating transcription genes, 
possesses RNA-binding activity and causes oxidative stress. 
Envelope glycoproteins  
(E1 and E2) 
Located on viral surface, responsible for HCV binding to the 
cell receptor allowing penetration of the virus into the cell. 
p7 ion  Forms calcium channels in ER membrane, essential for viral 
particle assembly. 
NS2  Protease. 
NS3  N-terminal  encodes  a  serine  protease.  C-terminal  contains 
ATP-dependent helicase that unwinds RNA or DNA strands. 
NS4A  Cofactor of NS3 protease. 
NS4B  Hydrophobic polyprotein that can induced ER stress. 
NS5A  Zinc binding phosphopolyprotein. Prevents apoptosis, induces 
oxidative stress, inhibits antiviral cytokine interferon alpha. 
NS5B  Error prone RNA-dependent RNA polymerase, catalyses RNA 
synthesis. Interacts with other viral proteins. 
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Figure 1.4: HCV viral life cycle. 1. Virus interacts with cell surface via receptors. 2. 
Virus fusion and uncoating releases viral RNA into the cell cytoplasm. 3. The RNA is 
translated into the polyprotein, and is cleaved by proteases. 4. RNA replication. 5. Virus 
is assembled into nucleocapsid. 6. Mature virus released from cell to infect other cells 
(Asselah and Marcellin, 2011). 
  Introduction  
  13 
1.3  Immune response to HCV infection 
1.3.1  Innate immunity 
Innate immunity is the first line of defence against pathogens. Responding rapidly, it is 
activated within  minutes to hours of  infection (Basset et al., 2003). Host response  is 
triggered when pathogen-associated molecular pattern (PAMP) of HCV are detected by 
host  pattern  recognition  receptors  (PRRs),  inducing  the  expression  of  antiviral  genes 
(Castello et al., 2010; Gale and Foy, 2005). Viral capsid and RNA are some examples of 
PAMP (Gale and Foy, 2005). PRRs are membrane-bound or secreted into circulation. 
Epithelial cells, macrophages, dendritic cells and mast cells all possess PRRs (Figure 1.5) 
(Basset et al., 2003). Viral recognition signal cascades activate nuclear factor κB (NF-κB) 
and  interferon regulatory  factors (IRF) 3, 5 and 7.  Inflammatory response to HCV  is 
mediated by chemokines and proinflammatory cytokines induced by NF-κB (Castello et 
al.,  2010;  Gale  and  Foy,  2005).  IRFs  activate  transcription  of  interferon  β  and  its 
secretion  from  infected  hepatocytes,  limiting  spread  of  HCV  (Castello  et  al.,  2010). 
Through  paracrine  action,  secreted  interferon  binds  to  interferon  receptors  of 
neighbouring  cells,  activating  the  JAK-STAT  pathway.  Enzymes  are  produced  that 
degrade mRNA, preventing protein synthesis and inhibiting viral replication (Gale and 
Foy, 2005). Interferon up-regulates major histocompatibility complex (MHC) class I and 
II  peptide  production,  promotes  T-cell  proliferation  while  preventing  apoptosis  and 
activates  innate immunity cells; dendritic cells  and  natural killer cells. Dendritic cells 
present viral antigen to other immune cells and secrete cytokines, activating T cells of 
adaptive immunity. Activated natural killer cells directly lyse infected cells through a 
cascade that activates apoptotic processes within infected cells (Castello et al., 2010). The 
innate immune system becomes inactive as infection persists but may become reactivated Introduction  
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during chronic infection with interferon based treatments (Castello et al., 2010; Neuman 
et al., 2008).    
 
 
 
Figure  1.5:  Pattern  recognition  receptors  and  their  role  in  innate  and  adaptive 
immune responses (Basset et al., 2003). 
 
1.3.2  Adaptive immunity 
Adaptive immune response is initiated by the innate immune system (Basset et al., 2003).  
Immature  CD4+  T  cells  are  activated  by  presentation  of  antigen  by  MHC  class  II 
molecules  of  antigen  presenting  cells.  An  inflammatory  Th1  response  is  induced, 
activating  macrophages,  B  cells  and  CD8+  T  cells  (Neuman  et  al.,  2008).    B  cells 
opsonise  HCV  with  antibodies,  targeting  the  virus  for  phagocytosis  by  macrophages. 
HCV antibodies are detectable about 8 weeks post infection, however it is unclear how 
effective the antibodies are at neutralizing HCV (Bowen and Walker, 2005). CD8+ T Introduction  
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cells  actively  clear  virus  by  eliminating  infected  cells  and  inhibiting  viral  replication 
through  the  recognition  of  MHC  class  I  molecules  and  secretion  of  interferon  γ  and 
tumour necrosis factor α. Apoptosis is induced in HCV infected cells  (Castello et al., 
2010; Neuman et al., 2008). Strong Th1 and CD8+ responses allow the resolution of 
HCV infection. A delayed or weak response results in chronic infection. A weak response 
may  occur  due  to  anergy  or  exhaustion  of  CD4+  T  cells  where  interleukin-2  is  not 
secreted or interferon γ function is disrupted (Neuman et al., 2008). Exhaustion of CD8 
has also been shown to occur in persistent HCV infections due to the up-regulation of the 
inhibitory receptor programmed death-1 (PD-1) (Urbani et al., 2006). Reduced interferon 
γ  production  favours  the  Th2  response.  Th2  cells  secrete  interleukin-4  promoting 
fibrogensis in the liver and interleukin-10 downregulating the Th1 response (Castello et 
al., 2010; Neuman et al., 2008).  
1.3.3  HCV evasion of immune system 
As stated before, HCV infection is only resolved in 15% of people. In most cases the 
infection persists and chronic HCV infection occurs (Castello et al., 2010; Hoofnagle, 
1997). Low host response is due to the ability of HCV to effectively evade the immune 
system (Figure 1.6). Non-structural HCV proteins actively suppress the innate immune 
system. NS3 and NS4A block IRF3 stimulation by inhibiting retinoic acid inducible gene 
I (Chisari, 2005;  Gale and  Foy, 2005). NS5A  induces the production of  interleukin-8 
which attenuates interferon stimulated genes that inhibit HCV replication (Gale and Foy, 
2005). HCV directly inhibits natural killer cells and dendritic cells (Castello et al., 2010; 
Eisenstein, 2011). Activation and function of natural killer cells are impaired by HCV 
envelope  proteins,  resulting  in  natural  killer  cell  anergy  or  exhaustion  (Mondelli, 
Varchetta, and Oliviero, 2010). Viral antigen presentation by dendritic cells is impaired, Introduction  
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decreasing the activation of B-cells and T-cells, weakening the adaptive immune response 
(Castello et al., 2010; Eisenstein, 2011).  
 
 
Figure 1.6: Evasion of the immune system by HCV (Eisenstein, 2011). 
 
Genetic variability enables HCV to evade the adaptive immune system. The error-prone 
RNA-dependent  RNA  polymerase  of  NS5B  facilitates  mutation  of  the  hypervariable 
region of the HCV genome encoding the viral envelope (Smirnova et al., 2011). This 
rapid mutation is one reason there is currently no vaccine for HCV (Gravitz, 2011). HCV 
escapes neutralizing B-cells antibodies since B-cell epitopes are mainly located within the 
hypervariable region of E2 (Chisari, 2005). Transmission of HCV directly between liver 
cells also prevents exposure of HCV to antibodies (Eisenstein, 2011). Recognition by T-Introduction  
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cells  is  prevented  by  mutations  in  T-cell  epitopes  thus  infected  cells  avoid  detection 
(Chisari, 2005). 
1.4  HCV models 
1.4.1  In vivo 
The  chimpanzee  is  susceptible  to  HCV  infection  with  many  features  of  the  infection 
similar to humans, except that chronic liver infection does not develop. However, the 
chimpanzee is not an ideal model due to expense, long gestation, ethics, and laws against 
euthanasia and in many countries research using chimpanzees is banned (Boonstra et al., 
2009; Dolgin, 2011). The northern tree shrew (Tupaia belangeri) is the only other known 
species that is naturally susceptibility to HCV. It has been found that over 3 years chronic 
hepatitis develops however, few labs have managed to establish a long-term infection and 
it is not established enough for drug trials (Amako et al., 2010; Dolgin, 2011). Transgenic 
and  chimeric  murine  models  are  available.  Transgenic  mice  encoding  HCV  proteins 
provide viral products that may be overexpressed but the whole viral life cycle is not 
represented. Chimeric mice have human livers and blood stem cells allowing a working 
immune system (Dolgin, 2011).  
1.4.2  In vitro 
Subgenomic replicons were the first in vitro HCV model. The neomycin resistance gene 
was incorporated into the genome, replacing the structural proteins of the Con1 strain of 
HCV (genotype 1a) to allow selection of virus that was capable of replicating HCV RNA 
(Figure  1.7).  Reporter  genes  such  as  luciferase  or  fluorescent  proteins  can  also  be 
incorporated  allowing  screening  and  direct  visualisation  of  HCV  replication.  These 
replicons produced high copies of HCV RNA but no virus was produced.  Introduction  
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Figure  1.7:  Genomic  structure  of  full  length,  subgenomic  and  chimeric  HCV 
replicons (Boonstra et al., 2009).  
 
Viral binding and entry into the cells was studied using the HCV pseudoparticles model. 
HCV envelop proteins E1 and E2 were incorporated into retroviruses or lentiviruses and 
allowed the identification of potential entry receptors (Boonstra et al., 2009). 
 
The  first  robust  model  of  the  full  HCV  life  cycle  came  from  virus  isolated  from  a 
Japanese patient with fuliminant HCV, JFH (genotype 2a) containing the full length viral 
genome (Kato et al., 2003). The virus was able to efficiently replicate in a hepatoma cell 
line,  Huh7  (Wakita  et  al.,  2005).  It  was  capable  of  releasing  infectious  virus  and 
replicated at a higher rate than Con1 (Boonstra et al., 2009). The virus produced by the 
Huh7 cultures was infectious for cell cultures and animal models such as chimpanzees 
(Wakita  et  al.,  2005).  Chimeric  replicons  can  be  produced  from  JFH  to  study  viral 
genotypes other than 2a (Boonstra et al., 2009).  Introduction  
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1.5  Iron Metabolism 
1.5.1  Role of iron in humans  
Iron is required by all mammalian cells for biological functions. It is required for the 
synthesis of haemoglobin and myoglobin for the transport of oxygen, DNA synthesis; as 
an enzyme cofactor in mitochondrial respiration and the citric acid cycle, and plays a role 
in the immune response (Weiss, 2002). The average adult male contains 35-45 mg of 
iron/kg of body weight. This is lower in premenopausal women as iron is lost through 
menstruation (Andrews, 1999).  
1.5.2  Acquisition and distribution of iron 
Only a small amount of iron is acquired from the diet, the remainder is obtained through 
iron  recycling  (1.5.3)  (Andrews,  1999).  On  average  about  1-2mg  of  iron  per  day  is 
absorbed through the duodenal enterocytes of the small intestine to compensate for iron 
lost  due  to  sloughing  of  cells  and  blood  loss.  The  amount  of  iron  absorbed  can  be 
enhanced when more iron is required such as during pregnancy or decreased during iron 
overloaded conditions (Hentze et al., 2010). Dietary iron comes in two forms; haem and 
non-haem  iron.  Haem  iron  is  acquired  from  the  ingestion  of  meat  in  the  form  of 
haemoglobin or  myoglobin  (Andrews and Schmidt, 2007). Haem  is absorbed through 
haem carrier proteins into the enterocytes where it is degraded by haem oxygenase-1. The 
iron in the form of Fe (II) is transported by ferroportin into the circulation where it is 
oxidised to Fe (III) by hephaestin before binding to transferrin for transport within the 
plasma (Kohgo et al., 2008). Haem iron is more efficiently absorbed than non-haem iron 
(Andrews and Schmidt, 2007). Non-haem iron or inorganic iron is derived from plants in 
the  form  of  Fe  (III)  (Kohgo  et  al.,  2008).  It  is  absorbed  at  the  brush  border  of  the 
duodenal enterocytes by the divalent metal transporter (DMT1) after being reduced to Fe Introduction  
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(II)  by  the  ferrireductase  cytochrome  b  (Hentze  et  al.,  2010).  Non-haem  iron  travels 
through the enterocyte from the apical surface to the basolateral surface for transport into 
circulation by ferroportin. Hephaestin oxidises the iron to Fe (III) which is then bound to 
transferrin for transport within the plasma (Andrews, 1999). This process is illustrated in 
Figure 1.8. Iron is distributed to the bone marrow, muscles, liver and macrophages for 
utilization or storage (Figure 1.9) (Andrews, 1999). 
 
 
                
 
Figure  1.8:  Absorption  of  iron  by 
duodenal enterocytes (Andrews, 1999). 
 
 
 
 
 
 
Figure  1.9:  Distribution  of  iron  in 
vertebrates (Andrews, 1999). Introduction  
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1.5.3  Utilisation and recycling of iron 
The bone marrow is the highest utiliser of iron, consuming almost two thirds of the total 
body  iron  (Andrews  and  Schmidt,  2007).  This  large  amount  of  iron  is  required  for 
erythropoiesis to synthesise haemoglobin. Erythrocytes have an average lifespan of 120 
days  (Kohgo  et  al.,  2008).  Upon  senescence  or  damage  of  erythrocytes, 
reticuloendothelial  macrophages located within the spleen phagocytose these cells and 
recycle  the  iron  (Andrews  and  Schmidt,  2007;  Hentze  et  al.,  2010).  Macrophages 
normally recycle up to 30 mg of iron per day but this may fluctuate during infection 
(Drakesmith  and  Prentice,  2008).  The  erythrocytes  are  phagocytosed  and  the  iron 
containing haem is catabolised by haem oxygenase-1. Some of the iron remains within 
the macrophage and is stored as ferritin while the rest is released into the plasma by 
ferroportin in the form of Fe (II). Iron is oxidised to Fe (III) by caeruloplasmin and bound 
to transferrin and transported to cells for utilisation (Figure 1.10) (Andrews and Schmidt, 
2007; Hentze et al., 2010; Kohgo et al., 2008). Recycled iron can be used by the bone 
marrow to produce more erythrocytes (Kohgo et al., 2008). Iron can also be utilized by 
muscles and other organs. Muscles require 10-15% of the body’s iron for the production 
of myoglobin (Andrews and Schmidt, 2007).  
1.5.4  Iron transport and storage 
Transferrin is the primary iron binding protein in the circulation which transports iron 
from sites of absorption and recycling to sites for utilisation or storage. Transferrin is 
normally only 30% saturated with iron. Saturation below 16% is indicative of an iron 
deficiency and iron overload occurs when saturation is above 45%. Non-transferrin bound 
iron accumulates in the circulation when transferrin is saturated above 60%, resulting in 
cell damage (Hentze et al., 2010).  Introduction  
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Figure 1.10: Recycling of iron by macrophages. 1. Senescent or damaged erythrocytes 
are phagocytosed by reticuloendothelial macrophages. 2. The erythrocyte is lysed. 3. The 
haem from within the erythrocyte is catabolised by haem oxygenase 1. 4. The iron is 
either stored within the macrophage as ferritin or transported by ferroportin in the form of 
Fe (II). The iron is oxidised to Fe (III) and bound to transferrin for transport within the 
plasma to sites of utilisation. 
 
 
Transferrin bound iron is transported into the cells by mainly transferrin receptor (TFR) 1 
and to a lesser extent by TFR2 while non-transferrin bound iron is transported by putative 
transporters Zrt- and Irt-like proteins (ZIP14) or DMT1 (Hentze et al., 2010; Kohgo et al., 
2008). Once inside the cell, iron is temporarily stored as both forms of iron (Fe II, Fe III) 
in  the  labile  iron  pool,  where  it  is  accessible  for  metabolic  processes.  Under  iron 
homeostasis control only 3-5% of the total cellular iron is located within the labile pool to Introduction  
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prevent  the  formation  of  reactive  oxygen  species  (ROS)  from  free  iron  (Kruszewski, 
2003). Excess iron is stored as ferritin mainly in hepatocytes of the liver (Figure 1.11). 
This iron can be mobilized when required by hydrolysis of ferritin to obtain Fe (II). The 
iron  is  transported  out  of  the  cell  by  ferroportin,  oxidised  to  Fe  (III)  and  bound  to 
transferrin in the plasma (Andrews and Schmidt, 2007). As stated above, iron can also be 
stored as ferritin within macrophages when iron is recycled from erythrocytes.  
 
Ferritin is an iron storage protein capable of storing up to 4500 atoms of iron. It is a 24 
subunit polymer consisting of heavy and light chains in a spherical structure (Andrews 
and Schmidt, 2007). There is 55% homology between heavy and light chains, with the 
heavy chain containing enzymatic oxidase activity (Ong et al., 2006). The centre of the 
ferritin sphere stores iron in the oxidative state, Fe (III) (Andrews and Schmidt, 2007). 
The storage of excess iron prevents iron-mediated cell damage (Hentze et al., 2010). 
 
 
 
 
 
 
Figure 1.11: Iron uptake by hepatocytes (Kohgo et al., 2008). Introduction  
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1.6  Iron homeostasis and regulation 
Iron homeostasis must be maintained to ensure that enough iron is available for biological 
functions while avoiding the toxicity of excess iron (Andrews and Schmidt, 2007). Excess 
iron  promotes  the  production  of  ROS  via  the  Fenton  reaction  that  damages  lipids, 
carbohydrates, proteins and nucleic acids causing cell death, fibrosis and carcinogenesis 
(Mueller, Afdhal, and Schuppan, 2006). Iron homeostasis is tightly regulated at both the 
systemic and cellular levels to maintain iron balance (Andrews and Schmidt, 2007).  
1.6.1  Systemic iron homeostasis 
Systemic iron homeostasis is primarily regulated at the level of absorption by hepcidin. 
Hepcidin is an antimicrobial peptide and a regulator of iron homeostasis that is produced 
by  hepatocytes. It is  -defensin  like  in  structure and contains 25 predominantly  basic 
amino acids that give it an overall positive charge (Falzacappa and Muckenthaler, 2005; 
Ong et al., 2006). Hepcidin binds ferroportin, a transmembrane transporter responsible 
for  transporting  iron  out  of  enterocytes,  macrophages,  and  hepatocytes  creating  a 
hepcidin-ferroportin  complex  which  is  then  degraded  in  proteasomes,  retaining  iron 
within the cells. Hepcidin inhibits DMT1 transcription within enterocytes, thus inhibiting 
apical  intestinal  iron  absorption  (Franchini,  Montagnana,  and  Lippi,  2010).  Overall, 
hepcidin  causes  a  decrease  in  intestinal  iron  absorption  and  iron  release  from 
macrophages that results in lower plasma iron levels (Ong et al., 2006). 
 
Hepcidin expression is regulated at the transcriptional level by iron and inflammation. 
The  pro-inflammatory  cytokine  interleukin-6  induces  the  transcription  of  hepcidin 
through the activation and binding of STAT3 to the hepcidin promoter. Interleukin-1 and 
toll-like  receptor  2  are  also  associated  with  enhanced  hepcidin  expression  (Wessling-Introduction  
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Resnick, 2010). The proteins bone morphogenetic protein (BMP6), hemojuvelin (HJV), 
haemochromatosis (HFE) and TFR2 also affect the iron-dependent regulation of hepcidin. 
Hepcidin  production  is  reduced  due  to  mutations  in  HFE  associated  with  the  iron 
overload disorder hereditary haemochromatosis (Andrews and Schmidt, 2007). Hepcidin 
is also regulated by erythropiesis, hypoxia and oxidative stress (Franchini, Montagnana, 
and Lippi, 2010). 
1.6.2  Cellular iron homeostasis 
Cellular iron homeostasis is regulated at the post-transcriptional levels by iron regulatory 
proteins (IRPs) (Hentze et al., 2010). IRPs bind to iron regulatory elements located in 
untranslated  regions  (UTR)  of  mRNA  coding  for  proteins  involved  in  iron  storage, 
transport and haem synthesis when cellular iron is limiting. IRPs can either bind  iron 
responsive element (IRE) in the 5’ or 3’ UTR of the mRNA. Binding to the IRE in 5’ 
region  of  genes  which  encode  for  ferritin  and  ferroportin,  inhibits  the  initiation  of 
translation for these proteins. Binding to the IRE in 3’ UTR of genes which encode for 
TFR1 and DMT1, inhibits nuclease digestion causing the molecule to be more stable and 
allow  further  production  of  the  proteins  (Figure  1.12)  (Andrews  and  Schmidt,  2007; 
Hentze et al., 2010). 
 
There are two forms of IRPs; IRP1 and IRP2. Either may bind to mRNA during iron 
limiting conditions to increase iron availability for the cell. IRP1 incorporates an iron-
sulphur cluster, acting as an iron sensor. During iron limiting conditions the iron cluster is 
absent, allowing binding of IRP1. In iron loaded cells, the cluster forms, preventing IRP1 
binding to mRNA and it converts to aconitase, an enzyme involved in the TCA cycle. 
IRP2 lacks the ability to form iron clusters and is degraded in the presence of excess iron 
(Figure 1.12) (Andrews and Schmidt, 2007; Hentze et al., 2010). Introduction  
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Figure 1.12: Regulation of cellular iron homeostasis via IRP (Hentze et al., 2010). 
 
Cellular iron homeostasis is also modulated by cytokines. Pro-inflammatory cytokines 
regulate the synthesis of ferritin at the level of transcription and translation (Ong et al., 
2006). Interleukin-1, interleukin-6 and tumour necrosis factor-α stimulate the production 
of ferritin. Interferon-γ induces DMT1 while inhibiting ferroportin (Weiss, 2009).   
1.7  Iron and infection 
Iron is required by micro-organisms; for the multiplication of bacteria when colonizing 
the host and for synthesis of viral particles (Mietzner and Morse, 1994; Weinberg, 2009). 
Iron is not present within the virion but is required by the host cell to synthesize viral 
particles  (Weinberg,  2009).  Iron  involvement  has  been  studied  in  human 
immunodeficiency virus, human cytomegalovirus, mouse mammary tumour virus, feline 
panleukopenia virus, canine parovirus and HCV (Drakesmith and Prentice, 2008; Haque Introduction  
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et al., 1996; Olynyk et al., 2007; Weinberg, 2009). Many mechanisms are used by innate 
immunity to limit the amount of iron available for invading pathogens thus inhibiting 
their growth and replication (Table 1.2). This is known as the iron withholding strategy of 
innate immunity (Ong et al., 2006).  
 
Anaemia is a disorder resulting from a reduction in the number of healthy red blood cells. 
It is a potential consequence of infection that may inadvertently arise in the  host as a 
result  of  defence  related  regulation  of  iron  metabolism  which  is  termed  anaemia  of 
inflammation. It can cause fatigue, pallor, decreased performance and effect the central 
nervous system (Andrews, 1999). In making iron less available for pathogens, the host 
defence also reduces iron availability, restricting the production of red blood cells and the 
delivery  of  oxygen  to  tissue  (Andrews,  1999;  Wessling-Resnick,  2010).  The 
inflammatory stress response pathways up-regulate hepcidin, causing the down-regulation 
of  ferroportin,  resulting  in  iron  retention  in  cells  (Wessling-Resnick,  2010).  During 
infection iron absorption and recycling of iron from macrophages or liver iron stores are 
decreased due to the up-regulation of hepcidin by the inflammatory cytokine interleukin-
6-STAT3  signalling  pathway  resulting  in  reduced  ferroportin  levels  (Figure  1.13) 
(Andrews  and  Schmidt,  2007;  Ong  et  al.,  2006).  Over-expression  of  hepcidin  in 
transgenic  mice  was  found  to  cause  anaemia  of  inflammation  (Falzacappa  and 
Muckenthaler, 2005).  
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Hepcidin
IL-6
IL-6R
STAT3
nucleus
Table 1.2: Iron proteins involved in host defence. 
Proteins  Iron 
metabolism 
function 
Defence function  References 
Hepcidin  Regulates iron 
homeostasis 
Antimicrobial properties, regulate 
iron levels 
1, 2, 3 
Lipocalin  Iron chelation  Binds bacterial siderophores  1, 3, 4 
NRAMP1  Macrophage 
iron transport 
Iron transporter  1, 3, 5 
Transferrin  Iron transport  Sequesters iron  1 
Lactoferrin  Iron binding 
protein in milk 
Blocks biofilm production, 
sequesters iron, antiviral 
properties 
1, 3, 5 
Ferritin  Iron storage  Iron withholding  1, 3,  6 
1.  (Ong et al., 2006) 
2.  (Falzacappa and 
Muckenthaler, 2005) 
 
 
3.  (Ward et al., 2011) 
4.  (Weinberg, 2009) 
5.  Weiss, 2009) 
 
 
6.  Wessling-Resnick, 
2010) 
 
Figure 1.13: Interleukin-6 induces the 
transcription of hepcidin through the 
activation and binding of STAT3 to the 
hepcidin promoter (Andrews and 
Schmidt, 2007). Introduction  
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1.8  HCV and Iron 
Iron and HCV have each been associated with oxidative stress and the formation of ROS 
(Figure 1.14) (Isom, McDevitt, and Moon, 2009). As mentioned before (section 1.6), iron 
overload can contribute to the formation of ROS through the Fenton reaction leading to 
lipid  peroxidation,  amino  acid  oxidation,  protein  and  DNA  damage  and  fibrosis 
(Franchini,  Montagnana,  and  Lippi,  2010;  Narang  et  al.,  2010).  The  liver  is  most 
vulnerable to oxidative stress due to the storage of excess iron within the hepatocytes and 
the infection of hepatocytes with HCV (Narang et al., 2010). The combination of HCV 
infection and  oxidative stress contributes to hepatocyte injury, inflammation, cirrhosis of 
the liver and HCC (Furutani et al., 2006).  
 
HCV replication can cause endoplasmic reticulum (ER) stress which disrupts the folding 
of proteins causing accumulation of unfolded or misfolded proteins. Both the HCV core 
and NS5A are capable of inducing ER stress without the presence of the whole viral 
genome (Benali-Furet et al., 2005; Isom, McDevitt, and Moon, 2009). To resolve the ER 
stress, unfolding protein response (UPR) is activated to degrade or refold the misshaped 
proteins,  however  HCV  inhibits  this  response.  The  ER  is  depleted  of  Ca
2+  reserves, 
allowing the mitochondria to take up the released Ca
2+ and form ROS. ER stress also 
induces apoptosis through caspase-3 cleavage (Isom, McDevitt, and Moon, 2009).   
 
Furutani and colleagues (2006) found higher levels of lipid peroxidation, mitochondrial 
injury and risk of HCC in transgenic mice carrying the HCV polyprotein that were fed a 
high-iron diet compared to mice fed a normal diet. The presence of whole or partial HCV 
genome was associated with increased hepatic iron, oxidative stress and liver cancer in 
the mice. Introduction  
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Figure 1.14: Relationship between iron, HCV, oxidative stress and ER stress (Isom, 
McDevitt, and Moon, 2009). 
 
Phlebotomy has been used to reduce iron levels in other iron overload disorders such as 
hereditary haemochromatosis (Andrews and Schmidt, 2007; Andrews, 1999). The iron 
depletion prevents the formation of ROS and the damage associated with ROS (Kato et 
al., 2007). In HCV, it has been found that phlebotomy improves serum ALT levels and 
liver histology, and decreases the risk of HCC progression without altering serum HCV-
RNA levels (Kato et al., 2007; Olynyk et al., 2007).    
 
There is some controversy over whether excess iron promotes or inhibits HCV infection. 
Clinical data suggest that iron is a co-morbidity factor for disease progression following 
HCV infection (Bonkovsky et al., 2002). Elevated serum ferritin levels and transferrin Introduction  
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saturation have been observed in 30-40% of chronic HCV patients (Boucher et al., 1997; 
Di Bisceglie et al., 1992). Iron overload has been associated with the increased risk and 
progression of clinical HCV disease (Drakesmith and Prentice, 2008). A role for HCV in 
increasing iron levels was shown by mouse studies that have observed that the hepcidin 
promoter region is inhibited by a CCAAT/enhancer-binding protein homology, which is 
up-regulated during HCV infection, thus increasing iron levels (Nishina et al., 2008).  
 
Promotion of HCV infection by iron is suggested by in vitro studies that have shown that 
iron  increases  HCV  translation  through  up-regulation  of  translation  initiation  factor  3 
(eIF3) and enhances translation by changing the binding affinity of internal ribosomal 
entry site cofactors (Cho et al., 2008; Theurl et al., 2004). In contrast, inhibition of HCV 
infection by iron has been suggested by in vitro studies which reported inactivation of the 
HCV NS5B protein, using sub-genomic replicons (Fillebeen et al., 2005). An aim of this 
project was therefore to determine whether the production of infectious virus is altered, 
increased or decreased, by the presence of  excess  iron using the Huh7 cell  model as 
described in section 1.4.2.   
 
Fillebeen and colleagues (2005) used hemin (a ferric iron containing porphyrin) and Fe-
SIH (a lipophilic, cell-permeable reagent) to donate iron to the human hepatoma cell line, 
Huh7, infected with HCV subgenomic replicons. Western blot and RT-PCR suggested 
that the presence of excess iron as shown by ferritin, the iron storage protein, decreases 
the expression of viral protein and RNA and that the iron binds to and inactivates viral 
NS5B. A subsequent study by these authors using the HCV JFH-1 model was published 
during the planning of this project. It found that Fe-SIH decreases the expression of viral 
RNA  in Huh7 cells  by 80% at day 4 post infection (PI) (Fillebeen and Pantopoulos, Introduction  
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2010). The methodology outlined in this publication was incompletely documented and 
some experiments lacked necessary controls; uninfected cell controls were not used and 
the  standard  of  western  blot  was  poor.  The  progression  of  infection,  percentage  of 
infected  cells  and  infectious  titre  were  not  determined.    Viral  mRNA  and  protein 
expression,  the  only  measurements  used  to  determine  the  effect  of  iron  on  HCV 
replication,  were  not  normalised.  Furthermore,  the  80%  reduction  in  viral  mRNA 
expression was only observed when cells were treated with the highest concentration of 
(50 μM) Fe-SIH tested. It was not evident if Fe-SIH was toxic to the cells as there was no 
measure of culture viability. Therefore, it was decided to continue with the proposed first 
aim of this project to clarify the effects of iron on HCV infection.  
 
Qiu (2009), a previous member of my group, found in a preliminary study that expression 
of  iron  metabolism  genes  altered  during  HCV  infection  of  Huh7  cells  and  that  the 
response changed depending on the extent of infection. Cultures with a low level of HCV 
infection  (<15%  infected)  were  observed  to  be  iron  deficient  while  iron  storage  was 
shown in cultures where all cells were infected. Therefore, the second aim of this study 
was to further investigate the effect of HCV infection on iron metabolism to substantiate 
these observations.  
1.9  Project aims 
Previous studies have given contradictory conclusions as to whether iron has promoting 
or inhibitory effects on HCV replication (Cho et al., 2008; Fillebeen and Pantopoulos, 
2010;  Fillebeen  et  al.,  2005;  Theurl  et  al.,  2004).  However,  none  of  these  studies 
investigated the effects of iron on the production of infectious HCV. In the present study, 
Huh7 hepatoma cells, which support the whole infectious cycle of HCV strain JFH-1 will 
be used to investigate the effects of excess iron.  Introduction  
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It was hypothesised that (1) the presence of excess iron affects HCV replication in vitro 
and that (2) iron homeostasis is altered by HCV replication. 
 
The hypotheses were tested by the following aims: 
1.  To determine if iron influences HCV replication in infected Huh7 cells. The cells 
were  treated  with  excess  iron  and  the  progress  of  infection  analysed.  This 
required: 
a)  Optimisation  of  the  iron  content  of  culture  media  to  detect  ferritin  by 
western blot.  
b)  Treatment  of  Huh7  cells  with  the  iron  donor,  ferric  ammonium  citrate 
(FAC)  prior  to  infection  with  HCV,  with  analysis  of  HCV  protein  by 
western blot, spread of HCV through the culture by immunostaining and 
assay of the titre of infectious virus produced. 
c)  Testing other iron donor compounds including holo-transferrin, hemin and 
Fe-PIH  (pyridoxal  isonicotinoyl  hydrazone)  with  analysis  as  above, 
including RNA by RT-PCR.  
2.  To determine whether HCV infection alters cellular iron status. Huh7 cells were 
analysed  for  iron  storage  levels  following  HCV  infection  by  quantification  of 
ferritin protein by western blot.   
a)  Cells will be infected for 1 and 2 weeks to determine if iron storage differs 
early and late after infection. 
b)  Should  iron  deficiency  or  excess  iron  storage  be  confirmed  then  the 
expression of cellular iron regulatory and transporter genes will be assayed 
by RT-PCR. Introduction  
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Observations from this study will provide a new insight on the interplay between iron and 
HCV.  This  will  provide  a  better  understanding  of  the  importance  of  iron  in  the 
pathogenesis of HCV infection. 
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Chapter 2:   Materials and Methods 
Section: Materials 
Chemicals not mentioned below were purchased from Merck or Sigma and were Analar 
or molecular grade as required. 
2.1  Cell culture 
Desferrioaxamine mesylate (DFO)            Sigma 
Dimethyl sulphoxide (DMSO)            Sigma 
Dulbecco’s modified eagle medium (DMEM), high glucose cat# 10313  Invitrogen 
Dulbecco’s phosphate buffered saline (PBS)         Invitrogen 
Ferric ammonium citrate (FAC)            Sigma 
Foetal bovine serum (FBS)              Invitrogen 
Gentamicin (80 mg in 2 mL)              Pfizer  
Hemin                   Sigma 
Holo-tranferrin (diferric transferrin)            Sigma 
L-glutamine (100x)                Gibco 
Trypan blue                ICN Biomedicals 
Trypsin-EDTA 0.5% solution (10x)            Invitrogen 
2.2  RNA analysis 
1-Bromo-3-chloropropane (BCP)            Sigma 
Agarose LE, Analytical grade             Promega 
Deoxyribonucleotide triphosphates (dNTPs) (10 mM)      Promega 
Dithiothreitol (DTT) (0.1 M)             Invitrogen 
DNA free
TM kit                Ambion Materials & Methods 
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Ethidium bromide (10 mg/mL)            Promega 
FastStart SYBR Green Master Mix            Roche 
Loading buffers 
  Loading buffer (2x)              Geneworks 
  Blue/orange loading dye (6x)           Promega 
Molecular weight markers 
  1kb ladder              New England Biolabs 
  100bp ladder (low)              Geneworks 
  PGEM® DNA marker            Promega  
Olgio dT (0.5 mg/mL)              Promega 
Reverse Transcriptase Reaction buffer (5x)          Invitrogen 
RNaseOUT
TM Recombinant Ribonuclease Inhibitor (40 U/μL)    Invitrogen 
SuperScript
TM III Reverse Transcriptase          Invitrogen 
TRI reagent                  Ambion 
2.3  DNA Analysis 
Bovine serum albumin (BSA) purified (100x) (10 μg/mL)    New England Biolabs 
NEB Buffer 3 (10x)              New England Biolabs 
NotI (10 U/mL)               New England Biolabs 
Proteinase K solution (20 mg/ml)            Invitrogen 
2.4  Protein analysis 
40% Acrylamide/bis-acrylamide            Bio-RAD 
Ammonium persulphate (APS)            Bio-RAD 
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Antibodies for western blot 
  Mouse monoclonal anti-β-actin (MAB1501)       Millipore 
  Goat anti-mouse IgG horseradish peroxidise       Santa Cruz 
  Rabbit anti-human ferritin            DAKO 
  Goat anti-rabbit IgG horseradish peroxidise        Santa Cruz 
BCA protein assay kit               Pierce 
Bovine serum albumin (BSA) (2 mg/mL) ultrapure      Thermo Scientific 
Coomassie Blue R-250              Sigma 
ECL Western Lightning Plus Kit            PerkinElmer 
Molecular weight markers 
  MagicMark
TM XP western protein standard (20-220 kDa)    Invitrogen 
  Novex® Sharp protein standard (3.5-260 kDa)      Invitrogen 
N,N,N’,N’-Tetramethylethylenediamine (TEMED)        Bio-RAD 
Nitrocellulose membrane            PALL Life Sciences 
NuPage 4-12% Bis-Tris gel 1.0 mm x 12 well        Invitrogen 
NuPage MOPS SDS running buffer            Invitrogen 
Protease inhibitor (complete mini protease inhibitor cocktail)    Roche   
Sodium dodecyl sulphate (SDS) electrophoresis grade      Bio-RAD 
Triton X-100                  BDH Merck 
Tween 20                  Sigma 
2.5  Immunohistochemistry 
Antibodies for immunohistochemical staining 
  Human serum from an HCV seropositive donor (donor 2) 
  Goat anti-human IgG horseradish peroxidise     Southern Biotech 
Goat anti-human IgG Dylight 488          Biolegend Materials & Methods 
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BD Perm wash
TM buffer            BD Biosciences 
DAPI nucleic acid stain              Invitrogen 
SIGMAFAST
TM 3,3’-Diaminobenzidine peroxidise (DAB)     Sigma 
2.6  Solutions and buffers 
1% TritonX/ 10% sucrose 
  Sucrose        1 g 
  Triton X-100        100 μL  
  dH2O          9.9 mL 
 
1.5% agarose gel 
  Agarose        0.75 g 
  1x TAE buffer       50 mL 
 
10% APS 
  APS          0.1 g 
  Made up to 1 mL with dH2O 
 
10% SDS 
  SDS          5 g 
  Made up to 50 mL with dH2O 
 
Antibody diluent (2% skim milk) 
  Skim milk powder      1 g 
  Made up to 50 mL with PBST 
 Materials & Methods 
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Blocking solution (5% skim milk) 
Skim milk powder      5 g 
  Made up to 100 mL with PBST 
 
Coomassie stain solution 
  95% methanol       237.5 mL 
  Acetic acid        50 mL 
  Coomassie Blue (R-250)    1 g 
  dH2O          212.5 mL 
 
Deionised water (dH2O) 
Water purified by reverse osmosis through a Milli-Q Plus system to yield deionised water 
with a purity of 18 Ω. 
 
Digestion buffer for DNA analysis 
  Tris HCl (1 M pH 8)      10 mL 
  NaCl (5 M)        4 mL 
  EDTA (0.5 M)        2 mL 
  10% SDS         2 mL 
  dH2O          82 ml 
 
Electrophoresis buffer for PAGE (10x) (pH 8.3) 
  Tris          29 g     
  Glycine        144 g 
  SDS          10 g Materials & Methods 
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  Made up to 1 L with dH2O 
 
Lysis buffer for protein extraction 
  Triton X-100        50 μL 
1M Tris-HCl pH 7.4      250 μL  
NaCl          87.66 mg 
Made up to 10 mL with dH2O 
Add 1 Complete mini protease inhibitor cocktail tablet to 10 mL lysis buffer 
 
NaOH (1M) 
  NaOH         4 g 
  Made up to 100mL with dH2O 
 
PBS (10x) (pH 7.4) 
  NaCl          80 g  
  KCl          2 g 
  Na2HPO4-7H2O      26.8 g 
KH2PO4        2.4 g 
Made up to 1 L with dH2O 
 
PBST (1x) 
  1x PBS        500 mL 
  Tween-20        1 mL 
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Resolving gel (10% gel)  
  40% Acrylamide/bis-acrylamide   1.875 mL 
  Resolving gel buffer      1.875 mL 
  10% SDS        75 μL 
  dH2O          3.75 mL 
  TEMED        7.5 μL 
  10% APS        25 μL (use more if old) 
 
Resolving gel buffer (1.5M Tris, pH 8.8) 
  Tris          90.75 g 
  Made up to 500 mL with dH2O 
 
Sample buffer for PAGE (4x) 
  2.5 M Tris pH 6.8      1 mL  
  30% SDS        2.7 mL 
  Glycerol        4 mL 
  BME          2 mL (add fresh) 
  Bromophenol Blue      25 mg 
  Made up to 10 mL with dH2O 
Aliquots stored in microfuge tubes at -20 ºC. 
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Stacking gel (4%) 
  40% Acrylamide/bis-acrylamide   0.5 mL  
  Stacking gel buffer      1.25 ml 
  10% SDS        50 μL 
  dH2O          3.2 mL 
  TEMED        7.5 μL 
  10% APS        30 μl (more used if old) 
 
Stacking gel buffer (0.5 M Tris, pH 6.8) 
  Tris          12 g 
  Made up to 200 mL with dH2O 
 
Towbin buffer (1x) 
  Tris           3 g 
  Glycine        144 g 
  Made up to 0.8 L with dH2O 
Add 0.2 volume methanol just before use 
 
Tris-acetate EDTA (TAE) buffer (50x) (pH 8) 
  Tris          24.2 g 
  Glacial acetic acid      57.1 mL 
  EDTA (0.5M)       100 mL 
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Triton X/NaOH diluent 
  1 M NaOH        1 mL 
  Triton X-100        100 μL 
  dH2O          9 mL 
 
Trypsin-EDTA (1x) 
  Trypsin-EDTA (10x)      1 mL     
  PBS (1x)        9 mL 
Section: Methods 
2.7  Cell culture 
Huh7 cells are a human hepatoma cell line (Nakabayashi et al., 1982). The cells were 
maintained in medium consisting of DMEM supplemented with L-glutamine (1 mL / 100 
mL), gentamicin (1 mL / 500 mL) and 10% foetal bovine serum (FBS) humidified in an 
incubator at 37°C with 5% CO2.  
2.7.1  Passage of Huh7 cells 
Huh7  cells  were  split  at  90-100%  confluency.  The  medium  was  removed  and  the 
monolayer washed 3 times with PBS. Trypsin-EDTA was added to cover the monolayer 
(1 ml / 25 cm
2) and incubated at 37°C for 1-3 mins until cells detached. The monolayer 
was tapped gently to loosen attached cells. Medium containing 10% FBS was added to 
cells to neutralise trypsin then the cell suspension was centrifuged at 585 g for 7 mins at 
room temperature (RT). The cell pellet was resuspended  in  medium and  incubated at 
37°C with 5% CO2 giving a passage routinely of 1:8, 1:20 or 1:40. Materials & Methods 
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2.7.2  Viable cell count 
Equal  parts  trypan  blue  and  cell  suspension  were  mixed  together  and  loaded  into  a 
Neubauer haemocytometer (0.100 mm Tiefe depth) and viewed under a microscope at 
100 x magnification. Unstained cells (viable cells) were counted and the total number of 
viable cells per mL calculated. 
Calculation:  
Cells / mL= average # viable cells per window x 10
4 / mL x dilution factor  
2.7.3  Cryopreservation of Huh7 cells 
Huh7 cells suspended in medium with 10% FBS were mixed with 10% DMSO slowly on 
ice  in  cryopreservation  vials.  The  vials  were  frozen  at  -80°C  in  polystyrene  racks  to 
ensure a cooling rate of 1°C /  min and then transferred to a liquid  nitrogen tank  for 
storage.  
2.7.4  Thawing cryopreserved Huh7 cells 
Cells from liquid nitrogen were thawed rapidly at 37°C in a waterbath. The cells were 
added to warm medium and centrifuged at 585 g for 7 mins at RT to remove DMSO. The 
cell pellet was resuspended in medium, transferred into a flask and incubated at 37°C 
with 5% CO2. 
2.7.5  Treatment of Huh7 cells with iron donor compounds 
Huh7 cells were seeded into trays and grown to 80-100% confluency. Cells were treated 
with 100 µM DFO, freshly prepared ferric ammonium citrate (FAC) in medium, 100 μM 
hemin,  5–30  μM  holo-transferrin,  or  50  μM  Fe-PIH.  PIH  (provided  by  Prof  D. 
Richardson (University of Sydney)) and  made up  in a 10  mM DMSO  stock. Fe-PIH 
complex was made by mixing 1 part 10 mM FeCl3 in 0.1 M HCl with 2 parts PIH and Materials & Methods 
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diluted  in  media  to  final  concentration  of  50  μM.  Controls  wells  were  treated  with 
medium only or PIH. The monolayers were checked for damage by microscopy and the 
cultures were incubated at 37°C with 5% CO2. 
2.8  HCV 
HCV strain JFH-1, a genotype 2a clone isolated from a Japanese patient with fulminant 
hepatitis C, that is capable of efficient replication in Huh7 cells was used (Wakita et al., 
2005). JFH-1 was originally provided to the group by Dr  Mark  Watson (Institute  for 
Immunology and Infectious Diseases) and grown in the same Huh7 cell line used by the 
group in iron metabolism studies. 
2.8.1  Virus stock 
A  stock  of  HCV  JHF-1  with  high  titre  was  required  to  infect  Huh7  cells  for  all 
experiments. An archive stock of virus was prepared and from that a working stock of 
virus was produced. The culture supernatant was harvested from a flask of Huh7 cells on 
days 6, 7 and 8 post infection (PI) with media replacement at the time of harvest. These 
supernatants  were  titrated  on  Huh7  cells  to  determine  the  titre  of  HCV  which  was 
detected on day 4 PI by immunofluorescence (IFA) for HCV (section 2.8.3). It was found 
that the supernatant harvested on day 8 contained 7.3 x 10
4 ffu/ml, giving the highest 
titred stock prepared by the group, this was used as the archive stock.  
 
To prepare the working stock of HCV, Huh7 cells in 75cm
2 flasks were incubated for 1 
hour with 3  ml of 1/16 archive stock. The supernatant was harvested on day 7, with 
complete media replacement and again on day 8. It was determined that the supernatant 
from day 7 contained 4.4 x 10
4 ffu/mL while day 8  contained 1.9 x 10
4 ffu/mL and thus 
the supernatant from day 7 was used as the working stock for subsequent experiments.        Materials & Methods 
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2.8.2  Lysis of cultures for determination of HCV titre 
Cell monolayers were harvested by scraping with a 1ml syringe barrel into 500 μL of the 
culture supernatant then lysed by passage through a fine needle. The samples were then 
sonicated for 5 minutes in a sonicating waterbath and stored in duplicate vials at -80ºC. 
Or else when specified, the supernatant from the culture was stored at -80ºC. 
2.8.3  Detection of HCV 
Infectious HCV was titrated on Huh7 monolayers which were stained on day 3 or 4. HCV 
infected cells were fixed with cold methanol overnight at -20ºC and permeabilised by 
incubations with 1% TritonX/ 10% sucrose for 5 minutes at RT then blocked with 1% 
goat serum for 15 mins at RT. HCV was indirectly stained with human serum for 1 hr at 
RT and goat anti-human IgG Dylight 488 for 1 hr at RT in the dark with detection by 
fluorescent microscopy and counterstained with DAPI (nuclear detection) for 10 mins at 
RT (IFA) or by IHC using secondary antibody conjugated with horseradish peroxidase for 
1 hr at RT and DAB (prepared according to the manufacturer’s instructions) for 10 mins 
at RT with reaction stopped by quenching with water. 
2.9   RNA studies 
2.9.1  RNA extraction and DNase treatment 
Huh7 cultures were washed once with PBS after removal of medium and lysed with 500 
µL / well cold TRI Reagent then transferred to 0.6 mL low adhesion tubes for 5 min at 
RT. BCP (50 µL / well) was added and tubes shaken vigorously for 30 secs. Tubes were 
incubated at RT for 10 mins then centrifuged at 12000 g for 15 mins at 4°C. The clear 
aqueous phase was transferred to new 0.6 mL tubes. Equal volume of isopropanol was 
added, mixed and incubated at RT to precipitate the RNA then centrifuged at 12000 g for Materials & Methods 
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15 mins at 4°C to pellet the RNA. The supernatant was removed; the pellet washed with 
75% ethanol and centrifuged at 12000 g for 5 mins at 4°C to pellet the RNA. The ethanol 
was removed and the pellet was air dried until clear. The RNA was dissolved in nuclease 
free  water  (~15  µL  /  tube)  and  incubated  overnight  at  4°C.  DNase  treatment  was 
performed on the RNA using a DNA-free kit. DNase buffer 1 10x (0.1 volume) and 0.5 
µL of rDNase 1 (2 U / µL) were added to the RNA, mixed and incubated at 37°C for 30 
mins. DNase inactivating reagent (0.1 volume) was added to the solution and incubated 
for 2 mins at RT followed by centrifugation at 10000 g for 1.5 mins at RT to pellet the 
inactivating reagent. The supernatant containing RNA was transferred into a new tube for 
storage at -80°C. 
2.9.2  RNA quantification  
The  quantity  and  purity  of  the  RNA  was  determined  on  a  Nanodrop  1000  (Thermo 
Scientific) spectrophotometer using 1 µL of neat sample. The absorbance was read at 260 
nm to quantify the RNA sample. The purity of the RNA was determined by the A260:A280 
and  A260:A230  ratio  where  1.8  -  2.0  represented  a  pure  sample.  Samples  were 
electrophoresed on a 1.5% agarose gel at 90 V for 1hr to verify the integrity of RNA.  
2.9.3  Reverse transcription   
RNA (2 ug) was annealed with 0.5 μg oligo DTs and 0.5 mM dNTPs for 5 mins at 65ºC 
to synthesis cDNA for each gene. Tubes were rapidly cooled in a metal cooling block for 
4 mins prior to adding an enzyme mixture of 0.2 μM DTT, 20 U RNaseOUT
TM and 200 U 
SuperScript
TM III Reverse Transcriptase. The reaction continued for 1 hr at 50ºC before 
inactivating the enzymes for 15 mins at 70ºC. The cDNA was stored at 4ºC and used 
within 3 days.    Materials & Methods 
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2.9.4  Real time polymerase chain reaction (RT-PCR) 
Gene  expression  was  quantified  by  RT-PCR  on  the  Rotorgene  RG3000
TM  (Corbett 
Research). Each reaction contained 1 μL of standard or cDNA and 14 μL of PCR master 
mix  (Table  2.1).  The  PCR  cycling  parameters  are  shown  in  Table  2.2.  The  melting 
temperature  was  obtained  and  copy  number  of  each  gene  was  determined  from  the 
standard  curve  analysed  by  Rotor-Gene  Real-Time  Analysis  Software  6.0  (Build  34). 
Standard  curves  were  only  used  for  analysis  with  coefficients  of  determination  (R
2) 
greater than 0.99.  
Table 2.1: PCR master mix. 
Reagent  1X 
Roche FastStart SYBR Green Master Mix  7.5 μL 
Primer mix (5uM forward and reverse) 
(see Table 2.3) 
0.75 μL 
Nuclease free H2O  5.75 μL 
TOTAL  14 μL 
 
Table 2.2: PCR cycling parameters. 
Steps  Temperature (°C)  Time (sec)  Number of cycles 
Denature  95  300  1 
Cycling 
  Denaturation 
  Annealing 
  Extension 
 
95 
See Table 2.3 
72 
 
15 
20 
20 
 
45 
Hold  72  30  1 
Melting curve  72-99  5   
Hold 2  40  30  1 Materials & Methods 
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Table 2.3: Primers for RT-PCR.  
Gene  Forward Primer 5’-3’ 
Reverse Primer 5’-3’ 
Anneal 
temperature (°C) 
β-actin  CT GGCACCACACCTTCTA 
GGTGGTGAAGCTGTAGCC 
59 
HCV (ReadR1 & 
SC27) 
GGTGCACGGTCTACGAGACCT 
TCCACCATFAATCACTCCC 
56 
Hepcidin  CTGTTTTCCCACAACAGACG 
CAGCACATCCCACACTTTGA 
59 
Peptidylprolyl 
Isomerase A (PPIA) 
ATGCTGGACCCAACACAAAT 
TCTTTCACTTTGCCAAACACC 
59 
TFR1  AGGAACCGAGTCTCCAGTGA 
ATCAACTATGATCACCGAGT 
53 
Mycoplasma  GGGAGCAAACAGGATTAGATACCCT 
TGCACCATCTGTCTCTCTGTTAACCTC 
62 
 
2.9.4.1  Standard curves for RT-PCR 
Standards were prepared by amplifying provided plasmids. Standard curves of each gene 
were prepared  from serial dilutions of a known copy  number (10
9 to 10
2). The copy 
number was determined using the size of the plasmid, concentration of the plasmid based 
on the assumption that 1 mole of DNA has 6.02 x 10
23 molecules and 1 μg of 1000 bp 
DNA  is  equivalent  to  1.52  pmol.  The  PCR  amplified  products  were  verified  by  gel 
electrophoresis on a 1.5% agarose gel for 1hr at 90 V and by the PCR amplicon melting 
point. It was found that the primers for TFR1 produced twin peaks on melting from both Materials & Methods 
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plasmid  and  cDNA  from  Huh7  cells.    Despite  changing  annealing  temperature  the 
abnormality persisted.  A fresh batch of primers were ordered and a single peak was then 
produced. The stock was stored at -80ºC but 3 months later was producing double peaks 
again. 
2.9.4.2  Molecular detection of mycoplasma by RT-PCR 
Mycoplasma status was determined by PCR. Huh7 cell pellets were digested overnight at 
55ºC with 25 μL digestion buffer and 0.25 μL Proteinase K, then mixed with 480 μL 
nuclease free H2O. PCR was setup as above using 1μL of the digested solution.  Controls 
consisted of water in place of DNA and also a sample of culture supernatant from a 
mycoplasma infected culture.  PCR product was run on a 1.5% agarose gel for 1 hr at 90 
V.  Bands  were  visualised  using  a  UV  transilluminator  and  a  Doc-Print  VXB  camera 
system. The expected product size of mycoplasma was 300 bp (Figure 2.1). 
2.10  Plasmid DNA 
2.10.1  Restriction enzyme digest 
Plasmid  DNA  for  human  albumin  (3086  bp)  and  human  peptidylprolyl  isomerase  A 
(PPIA) (3112 bp) within the vector pGEM-T (3015 bp), were made by Dr. Jane Allan, 
and hTFR1 (3322 bp) were digested with NotI. Purified plasmid (1-5 μL) was incubated 
at 37ºC for 2 hrs with NEB Buffer 3 (1x), bovine serum albumin (BSA) (100 μg/mL) and 
1 μL of enzyme. Gel electrophoresis was used to analyse the digested products. Samples 
were run on a 1.8% agarose gel containing ethidium bromide at 80 V for 1.5 - 2 hrs in 
TAE buffer with a 1 kb marker which was used to size and quantitate the product. Bands 
were visualised using a UV transilluminator and a Doc-Print VXB camera system (Figure 
2.2).  Materials & Methods 
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Figure 2.1: Mycoplasma detection. PCR products were analysed on a 1.5% agarose gel 
at  90V  for  1hr.  Lane  1:  100bp  ladder;  Lane  2:  Sample  for  Huh7  cells;  Lane  3: 
Mycoplasma positive control at 300bp; Lane 4: H2O control.  
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Figure 2.2: NotI digested pGEM-T containing Albumin, PPIA and TFR1 inserts. The 
digested plasmids were analysed on a 1.8% agarose gel at 80 V for 2 hrs. Lane 1: 1 Kb 
ladder; Lane 2: Albumin; Lane 3: PPIA; Lane 4: TFR1.  
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2.11  Protein studies 
2.11.1  Protein extraction 
Huh7 cells were washed once in PBS, scraped from the well, transferred into a microfuge 
tube and centrifuged at 250 g for 5 mins at RT. The supernatant was removed and the 
pellet was resuspended in lysis buffer (section 2.6) 2-3x volume of the pellet size. It was 
then incubated on ice for 30-60 min and centrifuged at 12000 g at 4°C for 20 mins. The 
protein containing supernatant was transferred into new microfuge tubes and stored at -
80°C. 
2.11.2  Bicinchoninic acid (BCA) protein assay 
The concentration of protein was determined by a BCA protein assay. BSA standards, 
diluted in Triton X/ NaOH dilutent (0-600 μg/mL), and diluted samples were added in 
triplicate at 20 μL per well to a 96 well tray. Reagent A (49 parts) and Reagent B (1 part) 
of the Pierce BCA protein assay kit were mixed to prepare the BCA working reagent and 
200 μL was added per well and incubated for 1 hr at 37ºC. The absorbance, A570, was 
measured on a plate spectrophotometer (FluoroStar Optima, BMG Labtech) and protein 
concentration determined from the standard curve.  
2.11.3  Western blot 
A 10% SDS-PAGE resolving gel (section 2.6) was prepared and allowed to polymerise 
for 45  mins  between Hoefer  vertical slab gel plates  with an overlay of 20% ethanol. 
Ethanol  was  then  removed  and  the  gel  washed  with  dH2O.  Gel  combs  were  placed 
between the plates and 4% SDS-PAGE stacking was allowed to polymerase on top of the 
resolving gel then stored O/N at 4ºC. The comb was removed and wells washed with 
dH2O. The gel was assembled in an electrophoresis tank and filled with electrophoresis Materials & Methods 
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buffer.  Protein  samples  (25-50  μg)  were  prepared  in  1:4  β-mercaptoethanol  (BME) 
containing Sample Buffer (section 2.6). Protein samples (20 μL) and molecular weight 
markers  (5  μL  each  MagicMark
TM  XP  and  Novex®  Sharp)  were  loaded  and 
electrophoresed until proteins migrated to bottom of gel at a constant current of 32 mA. 
Where specified, purchased pre-poured NuPAGE 4-12% Bis-Tris gels were used and they 
were electrophoresed with NuPage MOPS SDS running buffer at a constant current of 
110 V, otherwise conditions were the same.  
 
SDS-page gels were equilibrated in Towbin buffer (section 2.6) for 15 mins. The gel was 
assembled between 6 filter papers and nitrocellulose membrane soaked in Towbin buffer 
(Figure 2.3).The gel was electroblotted onto the nitrocellulose membrane at 172 mA for 1 
hr. To ensure protein transfer, the gel was stained in Coomassie Blue. 
 
 
Figure 2.3: Layout for SDS-PAGE gel to nitrocellulose membrane transfer. 
 
The nitrocellulose membrane was incubated in 5% skim milk blocking solution (section 
2.6) for 1 hr followed by 2 washes with PBS and incubated overnight with a primary 
antibody at 4ºC on a rocking platform. The following dilutions of primary antibodies 
were used:  Materials & Methods 
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Antibody  Dilution 
Β-actin (mouse anti-human) (Millipore)  1:1000 
Purified HCV seropositive human serum from HCV infected 
patients (polyclonal antibody) 
1:200 
Ferritin (rabbit anti-human) (DAKO)  1:2000 
 
The  membrane  was  washed  3  times  with  PBS  and  incubated  for  1hr  at  RT  with 
horseradish-peroxidase-conjugated  secondary  antibodies.  The  following  dilutions  of 
secondary antibodies were used: 
 
Antibody  Dilution 
Goat anti-mouse (Santa Cruz)  1:2000 
Goat anti-rabbit (Santa Cruz)  1:2000 
Goat anti-human (Southern Biotech)  1:2000 
 
Chemiluminescence reagents (ECL) were used to visualise the bound antibodies. Images 
were captured by VersaDoc Model 3000 (Bio-RAD) and quantified using Quantity One 
software (BioRad) Protein expression was normalised to βactin protein expression.  
2.12  Statistical analysis 
All quantitative results were expressed as mean ± SEM, n = 3 - 4 unless otherwise stated. 
The statistical significant differences between groups were determined by the Student’s 
unpaired  t-test  at  the  95%  confidence  level.  Results  were  considered  statistically 
significant when p values were less than 0.05.   
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Chapter 3:   Results 
3.1  Introduction  
HCV strain JFH-1, grown in Huh7 cells (Wakita et al., 2005) was used as previously 
optimised  by  Qiu  (2009).  Since  the  major  aims  of  this  study  were  to  determine  the 
influence of iron on HCV replication and to investigate whether  HCV alters iron storage 
in liver cells, it was necessary to optimise the iron content of the Huh7 cultures to provide 
a detectable level of the iron storage protein, ferritin (section 3.2). Several iron donor 
compounds were tested to determine their effects on HCV replication through the study 
of viral RNA and viral protein expression and infectious titre (section 3.3).  
3.2  Optimisation  of  the  iron  content  in  culture  media  to  allow 
detection of ferritin in Huh7 cells 
In  preliminary  studies  it  was  found  that  ferritin  was  not  detected  by  western  blot  in 
normal Huh7 cells grown in DMEM with 10% FBS. In order to detect changes in ferritin 
levels during experimentation, optimisation of culture conditions to increase basal ferritin 
levels was undertaken using iron supplementation. 
3.2.1  Testing two iron donor compounds, FAC and holo-transferrin  
Two compounds, FAC and holo-transferrin, were used to supplement culture media with 
iron. Previous work by the group has routinely used 30 μg/ml FAC and 30 μM holo-
transferrin to provide cultures with excess  iron. Therefore, normal Huh7 cell  cultures 
were treated with FAC (10, 15, 20 and 30 μg/ml) for 24 hours or holo-transferrin (5, 20, 
and  30  μM)  for  48  hours  (section  2.7.5).  Control  cultures  were  untreated  and  iron 
deficient cells were treated with the iron chelator, DFO (100 μM) for 24 hrs. Protein was 
extracted from cells and pooled from duplicate wells from a 6 well tray for determination Results 
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of cellular ferritin content. Total protein content was assayed by the BCA method (section 
2.11.1-2) and ferritin was quantified by western blot (section 2.11.3). Samples were run 
on a 10% SDS-PAGE gel in duplicate lanes for FAC treated cells (Figure 3.1a), and a 
single lane for holo-transferrin treated cells due to insufficient sample (Figure 3.1b). The 
level of ferritin protein was normalised to β-actin to allow for variation in protein loading 
(Figure 3.2). The untreated cells gave a negligible signal for ferritin. The ferritin signal 
was  reduced  by  the  presence  of  the  iron  chelator,  DFO  as  expected  (Figure  3.1a), 
however,  the  β-actin  signal  in  this  group  was  also  fainter  than  the  other  samples 
suggesting that less protein was  loaded. All concentrations of FAC significantly (p < 
0.05, 0.025) increased ferritin levels compared with the untreated Huh7 cells. The greatest 
effect was found for 10 μg/ml FAC, increasing ferritin levels by approximately 17-fold 
while 15, 20 and 30 μg/ml FAC increased ferritin levels by  7-11-fold compared with 
untreated cells (Figure 3.2a).  
 
The addition of iron by treatment of the cells with holo-transferrin also increased ferritin 
levels (Figure 3.1b). When normalised to β-actin, 20 µM holo-transferrin produced the 
greatest amount of ferritin protein, increasing levels by about 6-fold while 5 and 30 μM 
had less of an effect compared with untreated cells (Figure 3.2b). Overall FAC treatment 
was more effective than holo-transferrrin at raising ferritin protein expression, with 10 
µg/ml FAC, the lowest concentration tested, producing the highest ferritin concentration. 
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Figure 3.1: Ferritin detection by western blot in Huh7 cells. (a) Con, untreated; 24 hr 
FAC treatment (10, 15, 20, 30 μg/mL); DFO treatment (100 μM). (b) Con, untreated; 48 
hr holo-transferrin treatment (5, 20, 30 μM). Expected size of β-actin is 45 KDa and 
ferritin is 21 KDa. 
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Figure 3.2: Quantification of ferritin levels in uninfected Huh7 cells. (a) Cells were 
untreated (Con) or treated with DFO (100 μM) and FAC (10, 15, 20, 30 μg/ml) for 24 hrs. 
The results were normalised to β-actin and are expressed as average and range, n=2. * p < 
0.05; ** p ≤ 0.025 relative to Con. (b) Cells were untreated (Con) or treated with holo-
transferrin (5, 20, 30 μM) for 48 hrs. The results were normalised to β-actin, n=1.  
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3.2.2  Optimising the concentration of FAC  
In the previous experiment, 10 μg/ml of FAC, the lowest concentration tested, gave the 
highest concentration of ferritin. Therefore, a lower range of FAC concentrations was 
investigated to determine if lower concentrations of FAC would also give a robust signal. 
Since subsequent experiments, in which cultures would be infected with HCV, required a 
7 day time course the culture period was increased to 7 days before the cellular protein 
was  collected.  The  cells  were  treated  with  FAC  (0.1,  1,  5  and  10  μg/ml),  and  the 
incubation media was replaced on days 3 and 5. A single cell suspension was prepared 
from a pool of 4 replicate wells of a 6 well tray on day 7 and viability was determined by 
trypan blue exclusion (section 2.7.2). It was found that cell viability was not affected by 
0.1-10 μg/ml FAC (not shown), though the cell yield (Figure 3.3) may have been affected 
by tearing of the monolayer when replacing the media. Protein was extracted from the 
cells and ferritin expression was quantified by western blot as previously. Protein samples 
were run in triplicate lanes (Figure 3.4a) and ferritin expression was normalised to β-actin 
(Figure  3.4b).  In  this  western  blot,  β-actin  staining  was  low  however,  there  was 
insufficient protein to repeat the electrophoresis. 
 
FAC  treatment  (0.1-10  μg/ml)  increased  ferritin  levels  compared  with  untreated  cells 
(Figure 3.4a). The ferritin levels increased when the FAC concentration was raised from 1 
to  10  μg/ml  FAC,  while  0.1  μg/ml  was  only  slightly  increased  compared  with  the 
untreated  group  (Figure  3.4b).  From  these  data,  1  μg/ml  FAC  was  selected  as  the 
concentration  most  suitable  for  supplementation  of  the  media  as  it  was  the  lowest 
concentration to increase the ferritin to a level that was clearly detected by western blot. 
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Staining for β-actin in both western blots (Figure 3.1, 3.4a) had yielded a lower signal 
than  expected.  Before  performing  more  experiments  a  trial  of  antibody  batches  and 
conditions was undertaken. As a result new skim milk and a new vial of secondary goat 
anti-mouse antibody were employed in the following experiments. 
3.2.3  Summary  
It was found that FAC treatment increased ferritin expression to a greater extent than 
holo-transferrin  at  the  doses  tested.  Ferritin  levels  increased  as  FAC  concentrations 
increased  from  1  to  10  μg/ml,  higher  concentrations  did  not  increase  ferritin  levels 
further. Huh7 cell viability was not affected by 7 days of FAC treatment (0.1, 1, 5, 10 
μg/ml). The ferritin expression resulting from treatment of the cells with 1 μg/ml FAC 
was  readily  observed  by  western  blot  and  was  added  to  the  media  in  subsequent 
experiments.  
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Figure 3.3: Viable cell count from a pool of 4 replicate wells of Huh7 cells per group 
7 days after treatment with FAC at 0.1, 1, 5 and 10 μg/ml. Con, untreated control. Results 
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Figure 3.4a: Ferritin detection by western blot in Huh7 cells. (a) Cells were untreated 
(Con) or treated with FAC (0.1, 1, 5, 10 μg/ml) for 7 days.  
 
 
Con 0.1 1 5 10
0
10
20
30
40
* **
             FAC treatment (g/ml)
F
e
r
r
i
t
i
n
/

-
a
c
t
i
n
 
p
r
o
t
e
i
n
 
e
x
p
r
e
s
s
i
o
n
 
 
Figure 3.4 b: Quantification of ferritin expression in Huh7 cells. Cells were untreated 
(Con) or treated with FAC (0.1, 1, 5, 10 μg/ml) for 7 days. The results were normalised to 
β-actin and are mean ± SEM, n=3. * p < 0.05; ** p < 0.001 relative to Con. 
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3.3  Aim 1: Does iron influence HCV replication 
3.3.1  HCV infection of Huh7 cells in presence of excess iron provided 
by FAC  
HCV infection is associated with elevated serum ferritin levels and iron deposition in the 
liver (section 1.8). As discussed there is some controversy over whether the increased 
iron levels are beneficial or detrimental for HCV infection and replication. To determine 
the effects of iron on the replication of HCV, the amount of infectious virus produced in 
Huh7 cells was examined; cells were treated with FAC 1 day prior to infection.  
 
Huh7  cells  were  grown  in  culture  media  containing  1μg/ml  FAC  (baseline)  with  or 
without additional  FAC (5, 10, 20 μg/ml)  for 24 hours then  infected with  HCV at a 
multiplicity of infection (MOI) of 0.001 which should infect 80% cells by day 7 (Qiu, 
2009). Control groups included uninfected Huh7 cells as well as HCV infected Huh7 cells 
grown  in  baseline  media. The cell cultures were  monitored by IFA  for the spread of 
infection on days 4, 5, 6, 7 and 8 post infection (PI) to determine when 80% of the cells 
were infected.  
 
Ferritin was monitored to show the presence of storage iron. Protein was extracted and 
ferritin quantified by western blot on day 7 PI. Protein samples were run in triplicate lanes 
(Figure 3.5a, b). During the running of PAGE, bands widened and some β-actin bands 
merged, introducing inaccuracy in the determination of band intensity and quantification 
of ferritin when normalised to β-actin (Figure 3.5a -d). Staining for β-actin was stronger 
following  optimisation  of  the  staining  conditions  (section  3.2.2).  As  expected  from 
section 3.2.2, ferritin was detectable with baseline treatment. The appearance of a fainter  Results 
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Figure  3.5:  Ferritin  protein  detection  by  western  blot.  Cultures  are  treated  with 
baseline (1), 5, 10, 20 μg/ml FAC. (a) Uninfected (b) HCV infected, 0.001 MOI day 7 PI. 
(c)  Analysis  of  ferritin  levels  normalised  to  β-actin  for  uninfected  cultures  (d)  and 
infected cultures. Mean ± SEM, n=3. * p < 0.05 relative to uninfected.  
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ferritin signal in HCV infected compared to uninfected cultures was observed and could 
be caused by the reuse of antibody for the western blot (Figure 3.5a, b). Addition of FAC 
did not significantly alter the level of ferritin compared to baseline (Figure 3.5c, d) though 
there  were  higher  than  average  ferritin  levels  at  5  and  10  μg/ml  FAC  in  uninfected 
cultures. The  baseline and 10 μg/ml  FAC  may  be reduced  in HCV  infected cultures, 
though more replicates are required (Figure 3.5c, d).  
 
HCV protein was quantified by western blot. Protein samples were run in duplicate lanes 
(Figure 3.6a) and stained for HCV antigen using serum from a seropositive donor and 
normalised to β–actin (Figure 3.6b). HCV antigen was not detected in uninfected cultures. 
The serum detects HCV core antigen strongly. The HCV core signal appeared weakest in 
20 μg/ml FAC cultures but when normalised to β–actin, there was little difference in 
HCV core protein levels between FAC and baseline treatment (Figure 3.6b).  
 
A single cell suspension was prepared on day 7 PI from 15 replicate wells of a 24 well 
tray for each group and the number of viable cells determined by trypan blue exclusion. 
The presence of low levels of FAC (1 μg/ml) in the baseline media had no effect on the 
cell yield in the HCV infected cultures but the addition of higher concentrations of FAC 
reduced the cell yield by 25% compared to the uninfected cultures. The effect was not 
dose dependent as treatment with 5, 10, 20 μg/ml FAC resulted in a similar decline in cell 
yield (Figure 3.7).  
 
It was observed that HCV infection progressed from approximately 20% infected cells on 
day 4 PI to 75% infected cells observed on day 6 PI. Examples of IFA for HCV are 
shown in Figure 3.8. There was no obvious difference between cultures treated with  Results 
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Figure 3.6: HCV core detection by western blot. Cultures are treated with baseline 
(Con), 5, 10, 20 μg/ml FAC. (a) HCV core detection. β-actin is 45 KDa; HCV core is 20 
KDa. (b) Analysis of HCV core levels normalised to β-actin and expressed as average and 
range, n=2. 
b. 
a. Results 
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Figure 3.7: Viable cell count from 15 pooled Huh7 wells on day 7 PI. Cells were 
cultured in baseline media (1μg/ml FAC, con) or treated with FAC (5, 10, 20 μg/ml). n = 
1.  
 
 
             
 
Figure 3.8: Progression of HCV infection as determined by IFA for HCV antigen in 
baseline  cultures.  Huh7  cells  were  infected  with  MOI  of  0.001.  (a)  Day  4  PI 
approximately  20%  infected  cells  were  observed.  (b)  Day  6  PI  approximately  75% 
infected cells were observed. Blue, DAPI stained nuclei; Green, HCV antigen, x 200.  
a
. 
b
. Results 
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baseline, 5, 10 or 20 μg/ml FAC though it was difficult to quantitate as the monolayers 
were very confluent by day 6 PI. To quantitate these observations more accurately, flow 
cytometry was performed on day 7 PI. Cell fixation and intracellular staining for HCV 
was performed by Dr. Jane Allan and the samples were run on the flow cytometer and 
analysed by Irma Larma. The profiles for baseline, 5, 10 and 20 μg/ml FAC are shown in 
Figure 3.9a. There were 82.9% infected cells in the baseline group, 83.8% cells infected 
with 5 μg/ml FAC, 75.8% cells infected with 10 μg/ml FAC and 69.9% cells infected 
with 20 μg/ml FAC (Figure 3.9b).  
 
Supernatant was collected  from the  cultures and  assayed  for  infectious HCV  by IHC 
(section  2.8.3).  Titration  of  virus  showed  that  the  production  of  HCV  was  not 
significantly altered by the addition of excess  iron to the culture  when the data were 
expressed  relative  to  ffu/ml  (Figure  3.10a).  However,  when  expressed  relative  to  10
6 
cells, incubation with 10 μg/ml FAC gave a significantly (p < 0.01) higher titre of HCV 
than the baseline control cultures (Figure 3.10b).  
3.3.1.1   Summary 
Ferritin  was  produced  in  response  to  the  addition  of  FAC  to  cultures.  However,  the 
control HCV infected cultures had reduced ferritin levels compared to uninfected cultures 
and this will be investigated further in Aim 2 (section 3.4). The presence of increased 
intracellular iron, provided by FAC, reduced the number of cells in culture on day 7 after 
HCV  infection. No changes were  found  in the  ability of HCV to spread through the 
culture by assessment of the presence of HCV core protein. By flow cytometry there was 
a  decrease  from  84%  to  70%  infected  cells  on  use  of  20  μg/ml  FAC.  Despite  these 
observations, the amount of infectious HCV produced by Huh7 cells was not inhibited by 
5, 10, or 20 μg/ml FAC. Results 
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Figure  3.9:  Flow  analysis  of  HCV  infected  Huh7  cells.  (a)  Flow  profiles  of  FAC 
treatments. (b) Summary of percent HCV infected cells. Fixed cells were stained for HCV 
and 10,000 events analysed by flow cytometry. The closed histograms show staining with 
seronegative human serum and anti-human IgG while open histograms show staining for 
HCV antigen. 
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Figure  3.10:  Titres  of  infectious  HCV  collected  from  culture  supernatant,  0.001 
MOI, day 7 PI. Results are expressed relative to (a) ffu/ml and (b) 10
6 cells. Mean ± 
SEM, n=2-3.  * p < 0.01 relative to baseline. 
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3.3.2  Titration of copies of HCV RNA per infectious unit 
The  study  by  Fillebeen  and  Pantopoulos  (2010)  concluded  that  iron  inhibited  HCV 
replication by 80% based on RT-PCR. This observation is inconsistent with the findings 
from the previous experiment (section 3.3.1) which used an assay for infectious virus to 
quantify HCV levels. To determine if differences in methodology used to analyse the 
amount of HCV accounted for the different experimental outcomes between these studies, 
the relationship between infectious virus titre and viral RNA was examined.  
 
The HCV stock was serially diluted to give a known number of ffu and added to the same 
number  of  uninfected  Huh7  cells  in  order  to  see  a  RNA  pellet  during  experimental 
procedure. The RNA was reverse transcribed and the cDNA used for RT-PCR analysis 
(section 2.9). Two controls were  included  in the RT-PCR assays  i) water in place of 
cDNA and ii) cDNA derived from uninfected cells. Two independent RNA extractions 
were performed. The first RNA extraction consisted of log10 dilution series ranging from 
14520 to 440 ffu while an overlapping second series used 1440 to 4.4 ffu. The cDNA 
prepared from the first and the second RNA extractions was re-run in the same RT-PCR 
reaction to determine if variation in the results was due to extraction of RNA or RT-PCR 
reaction.  
 
The water control did not amplify, as expected, in all RT-PCR assays; the uninfected 
sample  (cDNA  0)  in  the  third  assay  gave  a  product  after  40  cycles  which  was  the 
incorrect melt peak (78.5 not 89-90) and therefore did not represent the expected product 
(Figure 3.11). Results 
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Figure 3.11: RT-PCR analysis for third run. (a) Raw data for cycling SYBR green. (b) 
Melt curve. (c) Standard curve for HCV.   10
5;   10
4;   10
3;   10
2;   10
1;   10
-1 
copies plasmid DNA; cDNA from HCV in Huh7 cells:   4400 ffu;   440 ffu;    44 ffu; 
 4.4 ffu;   0 ffu;   H2O. R
2= 0.999; N = 1.  
 
a. 
b. 
c. Results 
  75 
The  viral  RNA  concentrations of the diluted virus were  calculated  from the standard 
curve  and  copies  of  RNA  per  ffu  determined  (Table  3.1). It  was  found  using  higher 
concentrations of virus stock in the first experiment that 11 – 26 (average 18) copies of 
RNA were present per ffu. In the second experiment, where RNA was extracted from 
lower concentrations of virus, undetectable - 2 (average 1.0) copies of RNA per ffu were 
present. In the third run, there was a higher value for RNA copies per ffu (17.4) from 
cDNA from the first extraction compared to the second (average 2.5). Based on the copies 
of RNA per μl cDNA, it appeared that this difference resulted from the RNA extraction 
step. As described in more detail in the discussion (Chapter 4) these results suggested the 
differences in results between Fillebeen (2010) and the experiments presented in section 
3.3.1  were  not  attributed  to  the  measurement  of  viral  RNA  in  their  study.  An  80% 
reduction in HCV RNA would be evident by assay of infectious HCV titre. 
 
Table 3.1: Calculation of RNA per ffu of HCV from RT-PCR standard curve.  
Expt  ffu/ tube  RNA copies/μl cDNA  RNA copies/ffu 
 
1 
14520  54214  17.6 
4400  20425  26 
1452  4440  10.5 
440  (4673)  (35) 
 
2 
440  186  1.9 
220  34  0.9 
44  4, 10  0.3, 1.0 
4.4  (<0.01, < 0.01)  (<0.01, < 0.01) 
 
 
3 
4400 (1
st run)  16734  17.4 
440 (2
nd run)  476  3.6 
44 (2
nd run)  14.9  1.1 
4.4 (2
nd run)  3.7  2.7 
 
( ) – excluded from analysis Results 
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3.3.3  Infection of Huh7 cells by HCV in the presence of excess iron in 
the form of hemin, holo-transferrin and Fe-PIH 
The previous experiments concluded that treatment with the  iron donor FAC at 5-20 
μg/ml  did  not  affect  HCV  replication  under  the  experimental  conditions  used  which 
included 1 μg/ml FAC in the base culture media. However, Fillebeen and Pantopoulos 
(2010) and recently Bartolomei and his group (2011), concluded that excess iron inhibited 
HCV replication in Huh7 cells. Since these groups did not use FAC, one explanation for 
the difference in outcomes may be that this compound donated insufficient iron (section 
3.3.1). Therefore, the experimental procedure was modified and extended to test other 
iron donors, including 100 μM hemin which was used in the published studies. Holo-
transferrin was also included in the comparison because it is the physiological form of 
iron  found  in  the  circulation  in  vivo.  As  the  iron  donor, SIH,  used  by  Fillebeen  and 
Pantopoulos (2010) was synthesised by their group and not available, a substitute, PIH, 
which  was  likely  to  have  similar  properties  was  synthesised  by  Prof  D.  Richardson 
(University of Sydney). As in the previous experiments, 20 μg/ml FAC was used. The 
first comparison of iron donors was conducted using FAC, holo-transferrin, hemin and an 
untreated  control  group  as  PIH  was  not  yet  available.  Once  PIH  was  received,  the 
experiment was repeated with  hemin,  Fe-PIH and PIH as control.  Due to insufficient 
availability  of  Huh7  cells,  an  untreated  control  could  not  be  included  in  the  second 
experiment. 
 
The  experimental  procedure  was  further  modified  from  previous  experiments  since 
inhibition of HCV replication was only observed by Fillebeen and Pantopoulos (2010) if 
iron was added following HCV infection of Huh7 cells. Iron compounds were added to 
the cultures on day 1 PI. Hemin is known to be toxic therefore cells were pulsed with Results 
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hemin but the other iron donors were not removed. In the first experiment cells were 
incubated with hemin for 6 hours and in the second experiment for 24 hours then replaced 
with DMEM with 10% FBS. 
 
The time course was shortened from 7 days to 4 days to follow the protocol of Fillebeen 
and Pantopoulos (2010) and Bartolomei and his group (2011) therefore the virus dose was 
increased 10-fold to a 0.01 MOI. Culture media was DMEM / 10% FBS with 20 μg/ml 
FAC,  20  μM  holo-transferrin,  100  μM  hemin  or  50  μM  Fe-PIH  added  on  day  1  PI. 
Control groups included uninfected cells, no treatment and cells treated with the  iron 
chelator PIH.  
 
Protein  was  extracted  for  ferritin  and  quantification  of  HCV  core  by  western  blot  as 
before. Protein samples were run on a NuPAGE gel in duplicate lanes (Figure 3.12, 3.13) 
and normalised to β-actin (Figure 3.14). It was found for panel 1 (FAC, hemin and holo-
transferrin) that all treatments resulted  in  increased  ferritin  levels  above the untreated 
group (Figure 3.14a). FAC treated uninfected and HCV infected cultures had the highest 
ferritin levels (Figure 3.14a). FAC, holo-transferrin and hemin increased ferritin levels to 
a greater extent in infected than uninfected cultures (Figure 3.14a). It was found that Fe-
PIH treated  cultures  had  higher  ferritin  levels  compared  to  both  the  PIH  control  and 
hemin treated cells for uninfected cells (Figure 3.14b). Uninfected Fe-PIH treated cultures 
ferritin levels were significantly higher (p < 0.001) than uninfected PIH cultures with 
little  difference  in  ferritin  levels  between  treatment  with  PIH,  hemin.  Ferritin  was 
significantly (p < 0.01) higher in uninfected cultures treated with FE-PIH compared to 
HCV infected cultures (Figure 3.14b).  
 Results 
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Figure 3.12: Protein detection by western blot of Huh7 cells treated with iron donors 
FAC, holo-transferrin and hemin. Huh7 cells grown in media only (Con), or treated 
with  20  μg/ml  FAC,  25  μM  holo-transferrin  or  6hr  incubation  with  100  μM  hemin. 
Expression of (a) Ferritin in uninfected, (b) HCV infected cells and (c) HCV core protein, 
0.01 MOI day 4 PI.  
 
 
 
 
c. 
b. 
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Figure 3.13: Protein detection by western blot of Huh7 cells treated with PIH, Fe-
PIH and hemin. Cultures treated with 50 μM PIH, 50 μM Fe-PIH, and 100 μM hemin 
for 24 hrs. Expression of (a) Ferritin in uninfected, (b) HCV infected cells and (c) HCV 
core protein, 0.01 MOI day 4 PI.  
 
 
 
 
b. 
a. 
c. Results 
  80 
Con FAC Holo-TF Hemin
0
1
2
3
4
*
** **
*
* *
Treatment
F
e
r
r
i
t
i
n
/

-
a
c
t
i
n
 
p
r
o
t
e
i
n
 
e
x
p
r
e
s
s
i
o
n
       
PIH Fe-PIH Hemin
0
1
2
3
4
5
6
7 ***
HCV
Uninfected **
Treatment
F
e
r
r
i
t
i
n
/

-
a
c
t
i
n
 
p
r
o
t
e
i
n
 
e
x
p
r
e
s
s
i
o
n
 
 
Con FAC Holo-TF Hemin
0.0
2.5
5.0
7.5
Treatment
H
C
V
 
C
o
r
e
/

-
a
c
t
i
n
 
p
r
o
t
e
i
n
 
e
x
p
r
e
s
s
i
o
n
PIH Fe-PIH Hemin
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
*
Treatment
H
C
V
 
C
o
r
e
/

-
a
c
t
i
n
 
p
r
o
t
e
i
n
 
e
x
p
r
e
s
s
i
o
n
 
 
Figure 3.14: Analysis of ferritin and HCV core protein expression in Huh7 cells, 0.01 
MOI, day 4 PI. (a) Panel 1 iron donors and (b) Panel 2 iron donors for ferritin levels. (c) 
Panel 1 and (d) Panel 2 for HCV levels. Average and range, n = 2. * p < 0.05 relative to 
(a) uninfected / HCV con, uninfected Holo-tf and uninfected hemin. (d) hemin. ** p < 
0.01 relative to (a) HCV con. (b) uninfected Fe-PIH. *** p < 0.001 relative to uninfected 
PIH.  
 
 
 
 
 
a. Panel 1: Ferritin 
d. Panel 2: HCV core  c. Panel 1: HCV core 
b. Panel 2: Ferritin Results 
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The amount of HCV core protein appeared greater in FAC, holo-transferrin and hemin 
treated  groups  compared  to  untreated  HCV  infected  cells  (Figure  3.12c)  but  when 
normalised to β-actin, there was no significant differences between FAC, hemin and holo-
transferrin (Figure 3.14c). In the HCV infected cultures of panel 2, treatment with Fe-PIH 
produced a weaker signal for HCV core than with PIH and hemin treated cultures (Figure 
3.13c).  This  was  maintained  following  normalisation  to  β-actin,  with  little  difference 
between PIH and hemin (Figure 3.14d). The level of HCV core protein was significantly 
(p < 0.05) decreased when cultures were supplemented with Fe-PIH compared to hemin 
(Figure 3.14d). 
 
A single cell suspension was prepared on day 4 PI from 3 replicate wells of a 6 well tray 
for  each  group  and  the  number  of  viable  cells  determined  as  before  by  trypan  blue 
exclusion. In the holo-transferrin and hemin treated cells, Panel 1, some cells lifted from 
the wells. It was found that FAC (p < 0.05) and holo-transferrin (p < 0.01) treated, HCV 
infected cells had a significantly reduced yield of cells compared to the infected, control 
cells (Figure 3.15a). The number of cells seeded per well was decreased for the second 
experiment (Panel 2) to prevent cultures becoming overconfluent on day 4 PI. Less virus 
was added to maintain the MOI between experiments. It was found that on day 4 the cells 
were 90% confluent with hemin and 70 % confluent with Fe-PIH treatment compared 
with the control PIH treatment that was 100% confluent. In HCV infected and uninfected 
cells,  Fe-PIH  and  hemin  significantly  (p  <  0.05,  0.01,  0.001)  reduced  the  cell  yield 
compared to PIH treated cells (Figure 3.15b). 
 Results 
  82 
Untreated FAC Holo-TF Hemin
0
1
2
3
4
5
6
7
8
Uninfected
HCV
*
**
Treatment
1
0
6
v
i
a
b
l
e
 
c
e
l
l
s
 
PIH Fe-PIH Hemin
0
1
2
Uninfected
HCV
**
***
***
*
Treatment
1
0
6
v
i
a
b
l
e
 
c
e
l
l
s
 
Figure 3.15: Viable cell count on day 4 PI. (a) Panel 1: cells were untreated or treated 
with 20 μg/ml FAC, 25 μM holo-transferrin or 100 μM hemin for 6 hrs on day 1 PI. (b) 
Panel 2 used cultures seeded at lower cell density and they were treated with 100 μM 
hemin for 24 hrs, 50 μM Fe-PIH or 50 μM PIH on day 1 PI. Mean ± SEM, n =3. * p < 
0.05 relative to (a) HCV untreated, (b) uninfected PIH. ** p < 0.01 relative to (a) HCV 
untreated, (b) uninfected PIH. *** p < 0.001 relative to HCV infected PIH. 
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Huh7 cells were reseeded and fixed on the following day for HCV staining by IHC to 
determine the percentage of infected cells (Figure 3.16). In panel 1, it was observed that 
holo-transferrin produced the lowest percentage of infection (53%) and the untreated cells 
had the highest (75%). Due to some loss of monolayer during the IHC procedure only 1 
field of view was available for counting infected cells after holo-transferrin and hemin 
treatments. The level of HCV infection was also quantitated more accurately by flow 
cytometry, Cellular fixation, intracellular staining for HCV, flow cytometry and analysis 
was performed by Dr. Jane Allan. There was substantial HCV infection in all groups of 
panel 1. There were 77% infected cells in the control group, 70% infected cells with 20 
μg/ml FAC, 82% infected cells with 25 μM holo-transferrin and 77% infected cells with 
100 μM hemin. In panel 2, HCV infection ranged from Fe-PIH producing the lowest 
percentage (25%) of infection and PIH producing the highest (70%). Flow cytometry was 
not performed due to the low cell yield. 
 
RT-PCR was used to detect HCV RNA. RNA was extracted from Huh7 cells and reverse-
transcribed. RT-PCR analysis was performed in duplicate using 2 biological replicates 
(Figure 3.17), mRNA expression was normalised against β-actin and expressed relative to 
the total amount of RNA (Figure 3.18). The expression of HCV mRNA was measured for 
both panels of  iron donors. Controls consisted  of water  in place of cDNA, which as 
expected did not amplify, and uninfected cDNA samples.  
 
It was found for panel 1 that FAC and holo-transferrin did not alter HCV RNA levels 
(Figure 3.18a) however once normalised to β-actin, FAC (p < 0.05) and holo-transferrin 
(p < 0.001) HCV RNA levels were significantly lower than the untreated HCV infected 
control (Figure 3.18c). These results were observed irrespective of whether the data were  Results 
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Figure  3.16:  Extent  of  HCV  infection 
determined  by  IHC.  Huh7  cells  infected 
with MOI of 0.01 and stained on day 4 PI. (a) 
Panel  1.  (b)  Panel  2.  Brown,  HCV  antigen 
stained  with  HRPO  and  DAB;  Fast  green 
counterstain is green, cytoplasm. 
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Figure 3.17: Experimental design for mRNA analysis for each culture. 
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Figure 3.18: Analysis of HCV mRNA levels in infected Huh7 cells, 0.01 MOI, day 4 
PI. mRNA expression was measured by RT-PCR. (a) Panel 1 and (b) Panel 2 expressed 
relative to total amount of RNA. (c) Panel 1 and (d) Panel 2 normalised to β–actin and 
expressed relative to total amount of RNA. (e) Panel 1 and (f) Panel 2 normalised to β–
actin and expressed relative to 10
6 cells. Mean ± SEM, n = 4.  * p < 0.005 relative to con. 
** p < 0.001 relative to con or PIH. *** p < 0.05 relative to PIH. 
c. (HCV/β-actin)/ μg RNA  d. (HCV/β-actin)/ μg RNA 
e. (HCV/β-actin)/ 10
6 cells  f. (HCV/β-actin)/ 10
6 cells 
a. HCV/ μg RNA  b. HCV/ μg RNA Results 
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expressed per total μg RNA or 10
6 cells (Figure 3.18c, e). There was approximately a 
75%  reduction  in  HCV  RNA  expression  for  FAC  and  90%  for  holotransferrin  when 
normalised to β-actin (Figure 3.18c, e). Due to the high variation between the 2 biological 
replicates for hemin, it is unclear whether it had an affect on HCV RNA levels. For panel 
2, HCV RNA expression was significantly higher in the Fe-PIH treated compared to the 
PIH treated control cultures whether normalised to β-actin (Figure 3.18b) or expressed by 
total RNA or by 10
6 cells with approximately an 88% increase (Figure 3.18d, f).  
 
Supernatant was collected from the cultures and assayed for infectious HCV by IHC. 
Titration of virus showed that the production of HCV was not significantly altered by 
treatments when expressed relative to ffu/ml (Figure 3.19a, b).  However, when expressed 
relative to 10
6 cells, 20 μg/ml FAC gave significantly (p < 0.05) more virus than the 
untreated infected control (Figure 3.19c). Fe-PIH appeared to have the greatest affect, 
decreasing the titre of infectious virus (Figure 3.19b) however, when the reduction in the 
number of cells in the culture was taken into account there was no reduction in the HCV 
production (Figure 3.19d). 
3.3.3.1   Summary  
Use of FAC and holo-transferrin did not result in reduction of HCV RNA expression 
except when normalised to β-actin. These agents did not give a reduction in the number 
of  infected cells  by  flow cytometry;  nor was there a decrease  in  the amount of viral 
protein, normalised to β-actin, by western blot or the titre of infectious HCV in the culture 
supernatant. Fe-PIH did not reduce the amount of viral RNA compared to the control 
PIH, although cultures had  few  infected cells.  While the titre of  infectious HCV was 
lower in Fe-PIH treated cultures, it did not reach significance and was not different when 
calculated per 10
6 cells. Results 
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Figure 3.19: Titres of infectious HCV collect from culture supernatant, 0.01 MOI, 
day  4  PI.  Results  are  expressed  relative  to  ffu/ml  (a,  b)  or  10
6  cells  (c,  d).  Con  = 
untreated. Average and range, n = 2. * p < 0.05 relative to Con. 
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3.4  Aim 2: Does HCV infection alter cellular iron status  
In preliminary experiments it was found previously (Qiu, 2009) that HCV infection of 
Huh7 cells changed the levels of ferritin and expression of iron metabolism genes and that 
the response differed with the time or extent of infection. Iron deficiency was observed 
soon after infection when low levels of virus were present (15% infected cells determined 
by  IFA)  and  iron  deposition  later  when  all  cells  were  chronically  infected  (100% 
infected). In this investigation Huh7 cells were infected with a MOI of 0.01 to determine 
if HCV causes iron deficiency or iron storage depending on the duration or extent of 
infection. Cultures were analysed at early, day 7, and late, day 13, stages after infection.   
3.4.1  Optimisation of iron regulator and transporter genes for RT-
PCR quantification 
It was intended to measure RNA expression of genes that regulate iron metabolism and 
transport iron. Plasmids were available for quantitation standards for 9 genes (hepcidin, 
HFE,  TFR1,  TFR2,  ZIP14,  DMT1,  hemojuvelin  and  ferroportin,  and  β-actin  for 
normalisation).  Standard  curves  were  prepared  for  each  plasmid  following  previously 
optimised  run  conditions  (section  2.9.4)  (Qiu,  2009).  It  was  found  that  the  pTFR1 
produced  2  melt  peaks  on  amplification  of  the  plasmid,  although  gel  electrophoresis 
showed 1 product of the expected size, 307 bp (not shown). To resolve this problem a 
range of annealing temperatures were tested, using cDNA as a template without success. 
The primers were re-ordered and a single peak of the expected melt temperature was then 
produced. The stock was stored at -80ºC but 3 months later was producing 2 peaks again. 
A new primer stock was ordered for this experiment. Two new plasmids for albumin and 
PPIA were provided by Dr Jane  Allan. These 2 plasmids  were digested with NotI to Results 
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determine the plasmid concentration by gel electrophoresis (section 2.10.1, Figure 2.2) 
and a series of standards prepared. 
3.4.2  Early and late HCV infection of Huh7 cells maintained in 
baseline media  
Huh7 cells were grown in the baseline media (1μg/ml FAC) for 24 hours as optimised in 
section 3.2, then infected with HCV at a MOI of 0.001. Media were not changed to ensure 
that HCV remained in the cell culture media and fresh media were added to the cultures 
on days 2, 5, 7 and 10. Cultures were passaged 1/10 on day 7 when they were nearly 
confluent. 
 
Day  7  PI  infected  cultures  appeared  healthy  with  a  few  dead  cells  in  the  media.  
Significantly (p < 0.05) fewer cells were recovered at week 1 PI from the infected in 
comparison to the uninfected cultures (Figure 3.20). On day 7 and day 13 the monolayers 
were trypsinised, reseeded and fixed the next day to determine the percent of infected 
cells by IFA. At 2 weeks there were many dead cells in the culture supernatant and a pure 
single cell suspension could not be prepared due to cell clumping which affected the 
accuracy of the viable cell count. The week 2 cultures were sparse on reseeding (Figure 
3.21b). The difference in morphology between the week 1 and week 2 PI cultures was 
evident both before and after reseeding the cells. Cells were more spread out and the 
staining  of  HCV  was  more  diffuse  in  the  cytoplasm  in  the  week  2  PI  cultures. 
Approximately 86% cells were infected at week 1 PI and 100% were infected at week 2 
PI (Figure 3.21a, b).  Results 
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Figure 3.20: Viable number of Huh7 cells at day 7 PI, 0.001 MOI. Mean ± SEM; n = 
3. * p < 0.05 relative to uninfected. 
 
 
 
 
                   
             
Figure 3.21: Extent of HCV infection in Huh7 cultures by IFA. (a) Week 1 PI with 
approximately 86%  infected cells observed. (b) Week 2 PI with approximately 100% 
infected cells observed. Blue, DAPI stained nuclei; Green, HCV antigen, x 200.  
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Supernatant was collected from the infected cultures and assayed for infectious HCV by 
IHC. Titration of virus confirmed the production of HCV by both week 1 and week 2 
cultures (Figure 3.22a, b).  
 
HCV RNA was analysed by RT-PCR, as before (section 3.3.3), for week 1 and week 2 
infected and uninfected cultures. HCV was only amplified from the HCV infected week 2 
cultures (Figure 3.23). Since the HCV week 1 cultures had been shown to contain HCV 
by titration of virus, it is possible that the RNA had degraded. Due to uncertainty about 
the quality of RNA it was decided not to proceed with quantifying mRNA expression for 
the iron regulatory and transporter genes.  
 
HCV protein was monitored by western blot to show the occurrence of infection. Protein 
was extracted and HCV protein quantified by western blot on week1 and 2 PI. Protein 
samples were run on a NuPAGE gel in duplicate lanes and stained for HCV core antigen. 
Staining for HCV core protein was unsuccessful and the blot was discarded. The blot that 
had already been stained for ferritin and β-actin (see below) was then incubated with a 
different seropositive human serum, which gave a higher molecular weight HCV protein 
band at approximately 60 KDa that would not coincide with  ferritin or β-actin bands. 
There was a faint signal on the uninfected week 2 sample which could be due to non-
specific  binding or cross reacting antibodies as  my group has shown that this  human 
serum does produce a weak band in normal Huh7 close to 60 KDa. Both week 1 and 2 
cultures were  clearly HCV positive by  western blot (Figure 3.24a). 
 
Ferritin was also quantified by western blot. The protein samples were run in duplicate 
lanes (Figure 3.24a) and ferritin expression was normalised to β-actin (Figure 3.24b). At  Results 
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Figure  3.22:  Titres  of  infectious  HCV  collected  from  culture  supernatant,  0.001 
MOI, day 7 and 13 PI. Results are expressed relative to (a) ffu/ml or (b) 10
6 cells. Mean 
± SEM, n = 3. 
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Figure 3.23: Analysis of HCV RNA levels in infected and uninfected Huh7 cells, 
0.001MOI, week 2 PI. RNA expression was measured by RT-PCR and expressed 
relative to total amount of RNA. Mean ± SEM, n = 4. 
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Figure 3.24: Ferritin and HCV detection by western blot. Cultures were treated with 
baseline FAC and harvested 1 week PI or 2 week PI. (a) Ferritin and HCV detection. 
HCV is approximately 60 KDa. (b) Anaylsis of protein levels normalised to β-actin and 
expressed as average and range, n=2.  
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week 1 PI the ferritin  level was  higher  in the HCV  infected culture compared to the 
uninfected culture though it did not reach significance. The ferritin levels at week 2 PI 
were  surprising  with  the  uninfected  culture  containing  higher  levels  than  the  week  1 
uninfected culture. It is possible that the pinched appearance of the ferritin bands has 
caused  inaccuracy  in  quantitation  or  that  the  uninfected  and  infected  samples  are 
interchanged for week 2.   
3.4.3  Summary of Aim 2 
The  plasmids  and  primers  for  PPIA  and  albumin  are  established  for  use  as  qPCR 
standards. However, measuring TFR1 expression continues to be a challenge due to the 
primers. Design of a different primer set which would then have to be amplified and 
cloned into pGEM-T  would be the best approach. Although this experiment aimed to 
examine cells in iron deficient and iron storage phases, iron deficiency was not observed 
suggesting that further  optimisation of infection MOI and time of analysis after infection 
are required to give greater reliability of these phases of HCV infection of Huh7 cells. 
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Chapter 4:   Discussion 
To determine the effects of iron on HCV replication an in vitro cell culture model was 
used.  The  JFH-1  HCV  strain  which  contains  the  whole  viral  genome  is  capable  of 
efficient  replication  in  Huh7  cells,  producing  infectious  particles  (Kato  et  al.,  2003; 
Wakita et al., 2005). Fortunately Huh7 cells have been used previously in many studies of 
iron metabolism within my group (Herbison et al., 2009; Lee, Oates, and Trinder, 2003; 
Vecchi, Montosi, and Pietrangelo, 2010) providing the basis for these investigations.   
 
Before any infectious studies could be undertaken, it was required first to optimise the 
iron content of culture media to detect ferritin protein expression by western blot as it was 
not readily detectable in normal Huh7 cells grown in DMEM with 10% FBS. Qiu (2009) 
in her project with our group found that the use of FBS rather than newborn calf serum 
increased ferritin levels however, using FBS did not provide detectable ferritin in this 
project, possibly due to FBS batch variation. Therefore, media was supplemented with 
iron, provided by either FAC or holo-transferrin, as previously used by the group  for 
studies of iron metabolism (Herbison et al., 2009; Trinder et al., 1990).  Ferritin levels 
were  increased  to  a  greater  extent  by  FAC  than  holo-tranferrin  at  the  concentrations 
tested.  Addition  of  more  than  10  μg/ml  FAC  did  not  further  increase  ferritin  levels 
(Figure 3.2a, 3.8d). One μg/ml FAC was selected to supplement media as it produced a 
detectable signal without saturation, allowing for additional iron treatment.    
 
The main aim of this study was to determine if the presence of excess iron altered HCV 
replication and this was examined through analysis of HCV protein expression, spread of 
HCV through the culture and titre of infectious virus produced. When Huh7 cells were 
treated  with  various  concentrations  of  iron  provided  by  5-20  µg/ml  FAC  prior  to Discussion 
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infection, there was no substantial change in the ability of HCV to spread through the 
cultures, the expression of HCV core protein or the amount of infectious HCV produced 
with the exception of 10 µg/ml FAC which resulted in a low, but significant (p < 0.01) 
increase  in  virus titre  expressed relative to the  10
6 cells.  FAC treatment reduced cell 
number when cells were also infected. Overall there was no reduction in virus titre with 
FAC treatment. 
 
Fillebeen and Pantopoulos (2010) observed an 80% reduction in HCV RNA by RT-PCR 
when treated with 50 μM Fe-SIH. To determine if an 80% reduction in HCV RNA could 
have been detected as a fall in infectious titre and whether detection of infectious titre 
correlates with HCV RNA directly, the relationship  between  infectious  viral titre and 
viral RNA was examined. Viral RNA was calculated by RT-PCR to be 1-18 RNA copies 
per  ffu,  for  virus  stock  prepared  from  culture  supernatant.  To  determine  the  true 
correlation,  virus  would  have  to  be  purified  by  ultra-centrifugation  or  affinity 
chromatography (Prentoe and Bukh, 2011), to remove viral RNA released from apoptotic 
cells. Based on the relationship between viral RNA and ffu determined in section 3.3.2, 
an 80% reduction of RNA would have been detectable by assay of infectious titre (Figure 
4.1).  
 
Fillebeen and Pantopoulos (2010) only observed strong inhibition of HCV RNA when 
cells  were  treated  with  high  concentrations  of  the  iron  donor  (50  μM  Fe-SIH).  It  is 
possible that the FAC concentrations tested here were unable to donate enough iron to 
achieve the inhibitory effects found by Fillebeen and Pantopoulos (2010). It is estimated 
that 30 μg/ml FAC contains 5 μM Fe while 50 μM Fe-PIH contains 10-fold more iron (50 
μM Fe), although not all the iron would be donated to the cells.  Discussion 
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Figure 4.1: Titres of infectious HCV collected from culture supernatant, 0.001 MOI, 
day 7 PI. Results are expressed relative to (a) ffu/ml and (b) 10
6 cells and are based on 
data from Figure 3.10 calculated assuming 1 RNA copy per ffu. Red, based on 1 RNA 
copy per ffu (1:1).  
 
Mid-year, during the course of this project, a paper was published using the iron donating 
compound  hemin,  which  was  reported  to  down  regulate  HCV  replication,  providing 
similar  conclusions  to  Fillebeen  and  Pantopoulos  (2010)  (Bartolomei,  Cevik,  and 
Marcello, 2011). Bartolomei and colleagues (2011) used hemin treatment of Huh7 cells 
infected with a subgenomic replicon of HCV JFH-1 containing the luciferase reporter 
gene. They found that the replicon luciferase and NS5A levels were down regulated when 
treated with hemin for 6 to 24 hours. They confirmed the cells were proliferating which 
was a concern as hemin is known to be toxic. Fillebeen’s group (2005, 2007) used hemin 
initially however they discontinued it in favour of Fe-SIH (Ponka and Schulman, 1985) 
since  hemin  has  been  shown  to  block  subgenomic  HCV  replication  through  heme 
oxygenase 1 activity (Fillebeen and Pantopoulos, 2010). Neither Fillebeen’s group (2005) 
nor  Bartolomei’s  group  (2011)  determined  whether  the  inhibition  of  HCV  RNA 
production was due to heme oxygenase 1 activity. Bartolomei’s group (2011) concluded 
that it was due to iron since there was  normal  cell proliferation and as they  found  a 
b.  a. Discussion 
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similar  outcome  to  that  of  Fillebeen  and  Pantopoulos  (2010)  using  an  alternative 
lipophilic iron donor, Fe-SIH.  
 
In the present study inhibition of HCV replication was not found when Huh7 cells were 
exposed to FAC, other iron donor compounds were tested at concentrations used in the 
literature  (Bartolomei,  Cevik,  and  Marcello,  2011;  Fillebeen  and  Pantopoulos,  2010; 
Fillebeen et al., 2005). PIH was substituted for the  iron chelator, SIH (Fillebeen and 
Pantopoulos, 2010) and is also a lipophilic delivery vehicle. Fillebeen and Pantopoulos 
(2010) also saw no inhibition of HCV RNA and protein when cells were pre-treated with 
iron in the form of Fe-SIH. They found that HCV expression was inhibited maximally 
when iron was added 1 day after infection. They suggested that pre-treatment with iron 
increased the labile iron pool, causing iron to be stored as ferritin and was unable to bind 
to  NS5B,  thus  protecting  against  HCV  replication  inhibition.  In  the  current  study 
experimental  procedures  were  modified  so  that the  infection  time  course  was  shorter 
(from 7 days to 4 days), cells were iron treated 1 day post infection and HCV RNA was 
detected  by  RT-PCR.  It  was  found  previously  by  Qiu  (2009)  that  β-actin  and  PPIA 
expression  increased  when  cells  are  infected  with  HCV.  Fillebeen  and  Pantopoulos 
(2010)  did  not  normalise  their  results  to  housekeeping  genes,  while  Bartolomei  and 
colleagues (2011) normalised to GADPH. GADPH was not used as a housekeeping gene 
for this study as it is regulated by iron (Raje et al., 2007). Due to the possibility of an 
increase of β-actin during HCV infection, RNA expression was also expressed relative to 
total amount of RNA and number of cells. 
 
The toxicity of  hemin was avoided  by treating cultures with a 6 or 24 hour pulse of 
hemin. There was no significant change in cell yield between hemin treated and untreated Discussion 
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cells (Figure 3.13a). This supports Bartolomei and colleagues (2011) conclusion that a 
transient exposure to 100 μM hemin did not affect the viability of cells. The yield of 
infected  cells  with  FAC  treatment  was  20%  reducted  compared  to  controls,  a  trend 
observed in the previous experiment (Figure 3.7). Holo-transferrin also significantly (p < 
0.005) decreased cell number compared to untreated, infected cells (Figure 3.13a). The 
results showed that there was a significant reduction of cell yield with Fe-PIH treatment 
compared to the PIH control (p < 0.005 uninfected, p < 0.001 infected) (Figure 3.13b). 
This decline in number of cells could not be compared to the effects of SIH since this was 
not analysed in Fillebeen and Pantopoulos (2010).  
 
Following  FAC or holo-transferrin treatment there was  no decrease  in the  amount of 
HCV RNA. This was accompanied by a slight decrease in the number of infected cells 
(7%, 5% respectively) as determined by flow cytometry but no decline in the level of 
HCV core protein. HCV protein expression and virus production were also not affected 
by FAC or holo-transferrin. It is possible that staining for HCV core protein was not 
representative of all HCV proteins or that western blot was not as sensitive to change as 
the RT-PCR assay used by Fillebeen and Pantopoulos (2010). Low levels of HCV RNA, 
when infection titres are normal, could result if RNA was of low purity or was degraded. 
 
The inhibition of HCV RNA by hemin reported by the Bartolomei (2011) and Fillebeen 
(2005) groups was not found in this study. There was a trend for increased HCV RNA 
expression although due to high variation between biological replicates, significance was 
not found and verification is required. HCV protein levels increased but not significantly, 
while  viral  titre  was  unaltered.  Overall,  hemin  did  not  inhibit  HCV  replication.  The 
variation  in  outcome  in  results  from  those  of  the  other  groups  could  be  due  to  the Discussion 
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preparation of hemin. Hemin for this study was prepared in a NaOH stock (Klenow and 
Glei, 2009) while Bartolomei and collogues (2011) worked with a solution of hemin-
arginate containing ethanol and propylene glycol. It is unclear how hemin was prepared 
by Fillebeen et al (2005).  
 
Fe-PIH decreased the number of infected cells by 45%, there was less virus in the cultures 
though not less on a per cell basis and protein expression after normalisation was lower, 
although  not  significantly  due  to  the  high  standard  error.  Despite  this,  HCV  RNA 
expression was increased by 80%. One explanation which has to be considered for this is 
that the  Fe-PIH  and  PIH  tubes  were  accidently  switched  and  if  so  the  results  would 
coincide  with  the  80%  reduction  observed  by  Fillibeen  and  Pantopoulos  (2010). 
Therefore it is important to repeat this experiment to independently verify the results.         
 
There are different transport pathways for iron to enter cells, TFR1 is the receptor used 
for transferrin bound iron such as holo-transferrin and ZIP14 and DMT1  import non-
transferrin  bound  iron  such  as  FAC  (Chapter  1,  section  1.5.4).  Holo-transferrin  entry 
through  the  TFR1  would  be  regulated  by  iron  levels.  As  PIH,  SIH  and  hemin  are 
lipophilic delivery vehicles, Fe-PIH, Fe-SIH and hemin would enter cells across the cell 
membrane and therefore would not be regulated in the same manner as holo-transferrin 
transported by TFR1. In vivo studies by my group have shown that hemin is bound to the 
plasma protein haemopexin and is taken up by the hepatocytes by specific haemopexin 
receptor CD91. The pathway used by iron to enter the cell could affect the cellular iron 
levels and possibly the amount of iron available in the labile pool and the amount of iron 
stored as ferritin thus affecting HCV replication differently. Discussion 
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Another aim of this study was to determine whether HCV infection alters cellular iron 
status and this was examined through analysis of ferritin protein expression by western 
blot. When Huh7 cells were  grown  in  baseline  media (1 µg/ml  FAC),  morphological 
changes were observed between 15% infection and 100% infection of Huh7 cells that 
were  not  previously  seen  by  Qiu  (2009).  Altered  hepatocyte  morphology  has  been 
observed in chronic HCV infections where nuclei, mitochondria and ER were abnormal 
(Naas et al., 2005; Nepomnyashchikh et al., 1999).   
 
Cell death was observed in both week 1 and week 2 HCV infected cultures to a greater 
extent than uninfected cultures, indicating that cell loss was caused by infection although 
this was not observed in the first experiment using FAC (section 3.3.1). The cell death 
suggests apoptosis had occurred since HCV is known to induce oxidative stress, ER stress 
and formation of ROS resulting in apoptosis (Deng et al., 2008; Mishima et al., 2010; 
Sekine-Osajima  et  al.,  2008).  The  number  of  cells  in  week  1  infected  cultures  was 
significantly decreased by almost 50% compared to uninfected cultures (Figure 3.20). 
Since a large number of dead cells were not apparent in the culture supernatant it is likely 
that cell proliferation was affected. HCV has been shown to alter expression of the cell 
cycle, impairing progression and arresting the cycle in G1 (Marshall et al., 2005; Sarfraz 
et  al.,  2008).  Prolonged  infection  has  been  associated  with  viral  mutation  which  can 
increase viral titre and result in cytopathic effects (Russell et al., 2008).   
 
Qiu (2009) concluded there was iron deficiency in untreated, HCV infected culture with 
15% infection and saw iron storage, as ferritin, in culture with 100% HCV infected cells. 
Both ferritin levels of iron storage and high levels of ferritin were found in the current 
study.  Low  iron  levels  were  observed  when  cells  were  82%  infected  on  day  7  after Discussion 
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infection with 0.001 MOI, with 1 μg/ml FAC containing media replaced on days 3 and 5 
after infection (Figure 3.5e). There was a trend for less iron storage when the time course 
was shortened to 4 days PI and a 10-fold increase in MOI (0.01) was used without media 
replacement or iron supplementation. This resulted in 77% of cells infected although as 
the ferritin signal was barely visible, there was inaccuracy in the quantification (Figure 
3.14a). In  contrast,  iron  storage  was  observed  when  cells  were  86%  infected  (Figure 
3.24b). Iron storage was also observed in Panel 1 (Figure 3.14a) when Huh7 cells were 
70-82% infected with HCV and were treated with the iron donors FAC, holo-transferrin 
and hemin. It is still unclear if there is a point at which low ferritin levels shifts to iron 
storage. Further analysis of infection MOI and the time after infection for analysis are 
required. In the final experiment, high levels of iron storage in the highly infected cultures 
were found. The time after infection, MOI, use of 1 μg/ml FAC and replacement of media 
during the assay were variable factors between these experiments which may account for 
the increase in iron storage.  
 
As suggested before, free iron within the labile iron pool in the cytoplasm may bind to 
NS5B causing inhibition of HCV replication (Fillebeen and Pantopoulos, 2010). Thus it 
would be beneficial for HCV if free iron was stored as ferritin, preventing inhibition of 
HCV replication. This could explain why iron storage was observed during high levels of 
HCV  infection  of  Huh7  cells  (Qui,  2009;  section  3.4.2).  HCV  may  affect  iron 
metabolism, shifting free iron into the storage form as ferritin. This could be mediated by 
pro-inflammatory cytokines and hepcidin. As shown in chapter 1 (figure 1.13), the pro-
inflammatory cytokine  interleukin-6 up-regulates hepcidin, decreasing  iron absorption. 
Bartolomei’s group (2011) showed that the knockdown of hepcidin by RNA interference 
increased the intracellular ferritin levels and inhibited HCV replicon production. Other Discussion 
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viruses  such  as  HIV  and  cytomegalovirus,  affect  iron  transport  to  obtain  a  desirable 
environment for the virus (Drakesmith and Prentice, 2008). Qiu (2009) examined the 
effects  of  HCV  on  iron  metabolism  and  observed  alterations  in  iron  regulators  and 
transporters mRNA expression, observing high hepicidin levels in HCV infected Huh7 
cells. Further analysis of the effects of HCV on iron metabolism is required. 
 
Future directions for this study are to verify the results of the effects of iron on HCV 
replication  and  to  re-examine  whether  HCV  infection  alters  cellular  iron  status  to 
determine if these were true results. TFR1 could also be examined by western blot to help 
determine the cellular iron status. To obtain significance, results require verification using 
at least triplet replicates for the western blots. As planned, a panel of iron regulators and 
transporters should be tested to reveal how iron status is altered by HCV infection. The 
alterations in iron status following HCV infection could be tested in other hepatoma cell 
lines and chimeric replicons for other HCV genotypes to determine if these results pertain 
universally to HCV. An in vivo study of changes in iron status in chimpanzees following 
HCV infection would be beneficial in understanding the application and relevance of the 
in  vitro  data  to  HCV  infection.  Finally,  the  contributions  of  inflammation  and 
endoplasmic stress could be built into the model of interplay between iron and HCV by 
performing  a  microarray  of  cytokines  that  may  alter  iron  metabolism  during  HCV 
infection in Huh7 cells. 
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